The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

  • Lowest Price Guaranteed From USD 4,499

  • Published
    July 2019

  • Pages
    983

  • View Count
    27075

Example Insights

Cell Therapy Companies - Context Cell Therapy Companies - Primary Research Cell Therapy Companies - Social Media Analysis
Cell Therapy Companies - Development Pipeline Cell Therapy Companies - Development Pipeline Cell Therapy Companies - Clinical Trials
Cell Therapy Companies - Construct Analysis Cell Therapy Companies - Key Opinion Leaders Cell Therapy Companies - Development Pipeline
Cell Therapy Companies - Therapy CMO Cell Therapy Companies - Partnerships and Collaborations Cell Therapy Companies - Funding and Investments
Cell Therapy Companies - Market Forecast Cell Therapy Companies - Market Prediction Cell Therapy Companies - Promotional Strategies

 

Overview

The cancer therapeutics market is considered to be one of the most active segments within the pharmaceutical industry. In the past five years, the USFDA has approved more than 100 drugs for the treatment of different types of cancer. However, there is still a pressing need for more specific and potent drugs / therapies to combat this complex, life threatening clinical condition. It is also worth highlighting that, in the coming years, the number of cancer patients is anticipated to increase substantially along with the growing global population. According to the International Agency for Research on Cancer (IARC), close to 17 million new cases of cancer were diagnosed in 2018, worldwide. By 2040, it is estimated that the aforementioned number is likely to grow to 27.5 million. In fact, the global cancer burden is anticipated to increase by 70% in the next 20 years.

Among the current initiatives focused on developing targeted anti-cancer therapies, T-cell therapies (specifically CAR-T, TCR and TIL therapies) have emerged as a promising option owing to their capability to eradicate tumor cells from the body with minimal treatment-related side effects. These adoptive T-cell therapies (ACT) are based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. With the recent approval of KYMRIAH® (Novartis) and YESCARTA® (Gilead Sciences) for the treatment of CD19-positive relapsed / refractory leukemias and lymphomas, such ACTs have become a part of mainstream healthcare solutions.

Encouraging clinical trial results and therapeutic response rates achieved across various hematological cancers and solid tumors have further inspired research groups to focus their efforts on the development of these novel therapies. So far, more than 150 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential therapy candidates. In fact, multiple collaborations have been inked in the past decade between various therapy developers and academic / research institutes to advance the development of various pipeline candidates. The ongoing research activity in this field has also led to the discovery of several novel molecular targets. Further research and characterization of the aforementioned targets have significantly strengthened the research pipelines of companies engaged in this market. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the T-cell immunotherapies market is poised for success in the long-run as multiple product candidates are expected to be approved over the coming decade. 

Scope of the Report

The Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies (focusing particularly on CAR-T therapies, TCR therapies and TIL therapies). The report highlights the efforts of both industry players and academic organizations. Amongst other elements, the report features the following:

  • An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, highlighting the yearly trend of tweets, most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.
  • A detailed assessment of the current market landscape of T-cell immunotherapies with respect to type of therapy, type of developer (industry / non-industry), phase of development, target therapeutic indication(s), key target antigen(s), source of T-cells (autologous / allogenic), and route of administration. In addition, we have provided an overview of the competitive landscape, key challenges and anticipated future trends associated with CAR-T, TCR and TIL-based therapies.
  • Comprehensive profiles of marketed and mid to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
  • An analysis of the CAR constructs of clinical-stage CAR-T therapies based on the generation of CAR-T therapy (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector and type of co-stimulatory domain used.
  • A detailed analysis highlighting several key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical locations of eminent scientists / researchers involved in the development of T-cell therapies.
  • An analysis of the various CAR-T cell therapy focused clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend of initiation of such studies and distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies, especially in China.
  • An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity offered by oncological and non-oncological disease indications.
  • A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers. Further, it includes a relative competitiveness analysis of different T-cell immunotherapy-based gene editing platforms, based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
  • An analysis of the partnerships that have been established in the recent past, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of the investments that have been made into companies that have proprietary T-cell based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • A case study on other T-cell based therapies, apart from CAR-Ts, TCRs and TILs. It presents a detailed analysis of the approved / pipeline products in this domain, including information on the current phase of development, target therapeutic area(s), type of T-cells used and source of T-cells.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a list of contract service providers and in-house manufacturers that are involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for T-cell immunotherapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report includes potential sales forecasts of T-cell immunotherapies that are currently marketed or are in late stages of development. Additionally, it provides forecasts for the overall T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others) and [D] key geographies (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individualss:

  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Peter Ho (Director, Process Development, Iovance Biotherapeutics)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the T-cell immunotherapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapies. Moreover, it features detailed sections on the three major types of T-cell immunotherapies, namely CAR-T, TCR and TIL-based therapies, which are the main focus of the study.

Chapter 4 provides insights on the popularity of T-cell immunotherapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2019, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter highlights the most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.

Chapter 5 provides information on around 650 T-cell immunotherapies that are currently approved or are in different stages of development (clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules with respect to the type of therapy (CAR-T, TCR and TIL), type of developer(s), phase of development, target therapeutic area(s) and indication(s), key target antigen(s), source of T-cells (autologous / allogenic) and route of administration. Further, the chapter features the most active players (in terms of number of pipeline candidates) and a logo landscape, highlighting product developers in North America, Europe and the Asia Pacific region.

Chapter 6 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular targets of CAR-T and TCR therapies in hematological cancer and solid tumor space. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. In addition, we have presented an analysis of the CAR constructs being used in the clinical CAR-T therapies on the basis of generation of CAR-T therapy, type of binding domain, type of vector and type of co-stimulatory domain.

Chapter 7 presents an analysis of the CAR-T clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend and the distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies market in China.

Chapter 8 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 9 provides detailed profiles of the mid to late stage TCR therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 10 provides detailed profiles of the mid to late stage TIL therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 11 identifies the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the T-cell therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.

Chapter 12 provides a list of technology platforms that are either available in the market or under designed for the development of T-cell immunotherapies. A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers. Further, it includes a competitiveness analysis of different T-cell immunotherapy-based gene editing platforms, based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.

 Chapter 13 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 14 provides details on the various investments and grants that have been awarded to players focused on the development of T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2019, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 15 features details of other novel T-cell based therapies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. It presents a detailed analysis of the approved / clinical products in this domain, including information on the current phase of development, target therapeutic areas, type of cells, and source of T-cells. Additionally, we have provided a brief overview of the upcoming therapies, along with details on their mechanisms of action.

Chapter 16 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 17 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.

Chapter 18 features an elaborate discussion on the future commercial opportunity offered by T-cell therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others) and [D] key geographies (North America, Europe and Asia Pacific).

Chapter 19 highlights the key promotional strategies that are being implemented by the developers of the marketed products, KYMRIAH® and YESCARTA®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 20 includes brief company profiles of the leading players in the T-cell immunotherapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 21 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 22 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Chief Executive Officer, Cell Therapies), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Miguel Forte (Chief Operating Officer, TxCell), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Peter Ho (Director, Process Development, Iovance Biotherapeutics), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital) and Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado).

Chapter 23 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 24 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
 
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
3.7.1. History of Development
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane (TM) Domain
3.7.2.3. Endodomain
 
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration of CAR-T Cell Therapies
3.7.6. Case Study: CD19 CAR-T Cell Therapies
3.7.6.1. Other Important Biological Targets for CAR Development
3.7.7. Challenges Associated with CAR-T Cell Therapies
3.7.7.1. Competitive Risks
3.7.7.2. Clinical Risks
3.7.7.3. Regulatory Risks
3.7.7.4. Commercial Risks
 
3.8. T-Cell Receptor (TCR)-based Cell Therapy
3.8.1. History of Development
3.8.2. Anatomical Layout of TCR
3.8.3. Development of TCR for Therapy
3.8.4. Differences between CAR-T and TCR-based Therapies
 
3.9. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
3.9.1. History of Development
3.9.2. Development of TILs for Therapy
3.10. Key Challenges and Roadblocks
 
4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. T-Cell Immunotherapies: Trends on Twitter
4.2.1. Historical Trend in Volume of Tweets
4.2.2. Trending Words / Phrases on Twitter
4.2.3. Most Popular Drugs on Twitter
4.2.4. Most Prolific Authors on Twitter
4.2.5. Most Popular Indications and Target Antigens
 
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. T-Cell Immunotherapies: Overall Market Overview
5.2.1. Analysis by Type of Product
5.2.2. Analysis by Type of Developer
5.2.3. Analysis by Phase of Development
5.2.4. Analysis by Target Oncological Indications
5.2.4.1. CAR-T Cell Immunotherapies: Popular Target Indications
5.2.4.2. TCR-based Immunotherapies: Popular Target Indications
5.2.4.3. TIL-based Immunotherapies: Popular Target Indications
5.2.5. Analysis by Popular Target Antigens (CAR-T Cell Therapies and TCR-based Therapies)
5.2.6. Analysis by Source of T-Cells
5.2.7. Analysis by Route of Administration
5.2.8. Analysis by Patient Segment
5.2.9. Analysis by Type of Therapy
5.2.10. Key Industry Players: Analysis by Number of Therapies in Development
5.2.11. Key Non-Industry Players: Analysis by Number of Therapies in Development
 
6. KEY INSIGHTS
6.1. Chapter Overview
6.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigens
6.2.1. Popular Targets Related to Hematological Malignancies
6.2.1.1. Competitive Landscape of CD19 CAR-T Cell Immunotherapies
6.2.1.2. Clinical Trial Results of Prominent CD19 CAR-T Cell Immunotherapies
6.2.1.3. Competitive Landscape of BCMA CAR-T Cell Immunotherapies
6.2.1.4. Clinical Trial Results of Prominent BCMA CAR-T Cell Immunotherapies
 
6.2.2. Solid Tumors: Popular Targets
6.2.2.1. Competitive Landscape of Meso CAR-T Cell Immunotherapies
6.2.2.2. Clinical Trial Results of Prominent Meso CAR-T Cell Immunotherapies
6.2.2.3. Competitive Landscape of GD2 CAR-T Cell Immunotherapies
6.2.2.4. Clinical Trial Results of Prominent GD2 CAR-T Cell Immunotherapies
 
6.3. T-Cell Immunotherapies: Key Opinion Leaders
6.3.1. CAR-T Cell Therapies: Key Opinion Leaders
6.3.2. CAR-T Cell Therapies: Most Prominent Key Opinion Leaders
6.3.3. TCR-based Therapies: Key Opinion Leaders
6.3.4. Most Prominent Key Opinion Leaders
6.3.5. TIL-based therapies: Key Opinion Leaders
6.3.6. TIL-based Therapies: Most Prominent Key Opinion Leaders
 
6.4. T-Cell Immunotherapies: CAR Construct Analysis
6.4.1. Analysis by Generation of CAR
6.4.2. Analysis by Type of scFv Antibody
6.4.3. Analysis by Type of Vector
6.4.4. Analysis by Type of Co-Stimulatory Domain(s)
 
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Clinical Trial Analysis
7.2.1. Methodology
7.2.2. Analysis by Trial Registration Year
7.2.3. Geographical Analysis by Number of Registered Trials
7.2.4. Case Study: CAR-T Cell Therapy Market in China
7.2.4.1. Factors Contributing to the Growth of CAR-T Cell Therapy Trials in China
 
8. CAR-T CELL THERAPY PROFILES
8.2. KYMRIAH® / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. Current Development Status
8.2.3. Key Clinical Trial Results
8.2.4. Dosage Regimen, Price and Manufacturing
 
8.3. YESCARTA® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
8.3.1. Therapy Overview
8.3.2. Current Development Status
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen, Price and Manufacturing
 
8.4. JCAR (Juno Therapeutics)
8.4.1. Therapy Overview
8.4.2. Current Development Status
8.4.3. Key Clinical Results
8.4.3.1. JCAR014
8.4.3.2. JCAR017
8.4.3.3. JCAR018
8.4.3.4. JCARH125
8.4.4. Dosage Regimen and Manufacturing
 
8.5. bb2121 (bluebird bio / Celgene)
8.5.1. Therapy Overview
8.5.2. Current Development Status
8.5.3. Key Clinical Trial Results
8.5.4. Dosage Regimen and Manufacturing
 
8.6. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen Biotech)
8.6.1. Therapy Overview
8.6.2. Current Development Status
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing
 
8.7. CD19 CAR-T Cell Therapy (Takara Bio)
8.7.1. Therapy Overview
8.7.2. Current Development Status
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing
 
8.8. Dual Targeting CAR-T Cell therapies (Autolus)
8.8.1. Therapy Overview
8.8.2. Current Development Status
8.8.3. Key Clinical Trial Results
8.8.3.1. AUTO2
8.8.3.2. AUTO3
8.8.4. Dosage Regimen and Manufacturing
 
8.9. CAR-T Cell Therapies (Sinobioway Cell Therapy)
8.9.1. Therapy Overview
8.9.2. Current Development Status
8.9.3. Dosage Regimen and Manufacturing
 
9. TCR-BASED THERAPY PROFILES
9.1. Chapter Overview
9.2. SPEAR T-Cells (Adaptimmune / GlaxoSmithKline)
9.2.1. Therapy Overview
9.2.1.1. SPEAR T-Cells Technology Platform
9.2.1.2. NY-ESO SPEAR T-Cell
9.2.1.3. Mage-A10 T-Cell Therapy
9.2.1.4. AFP T-Cell Therapy
9.2.1.5. Mage-A4 T-Cell Therapy
9.2.2. Current Development Status
9.2.3. Key Clinical Trial Results
9.2.4. Dosage Regimen and Manufacturing
 
9.3. IMCgp100 (Immunocore)
9.3.1. Therapy Overview
9.3.2. Current Development Status
9.3.3. Key Clinical Trial Results
9.3.4. Dosage Regimen and Manufacturing
 
9.4. ALT-801 (Altor BioScience)
9.4.1. Therapy Overview
9.4.2. Current Development Status
9.4.3. Key Clinical Trial Results
9.4.4. Dosage Regimen
9.4.5. Patent Portfolio
 
9.5. JTCR016 (Juno Therapeutics)
9.5.1. Therapy Overview
9.5.2. Current Development Status
9.5.3. Key Clinical Trial Results
9.5.4. Dosage Regimen and Manufacturing
 
9.6. CMD-602 / WT1 TCR Therapy (Cell Medica)
9.6.1. Therapy Overview
9.6.1.1. History of Development
9.6.2. Current Development Status
9.6.3. Key Clinical Trial Results
9.6.4. Dosage Regimen and Manufacturing
 
9.7. TBI-1301 (Takara Bio)
9.7.1. Therapy Overview
9.7.2. Current Development Status
9.7.3. Key Clinical Trial Results
9.7.4. Dosage Regimen and Manufacturing
 
10. TIL-BASED THERAPY PROFILES
10.1. Chapter Overview
10.2. Autologous TIL Therapies (Iovance Biotherapeutics)
10.2.1. Therapy Overview
10.2.2. Current Development Status
10.2.2.1. LN-144
10.2.2.2. LN-145
10.2.3. Key Clinical Trial Results
10.2.4. Dosage Regimen and Manufacturing
10.2.5. Patent Portfolio
 
10.3. TIL (Nantes University Hospital)
10.3.1. Therapy Overview
10.3.2. Current Development Status
10.3.3. Key Clinical Trial Results
10.3.4. Dosage Regimen and Manufacturing
 
10.4. TIL (Netherlands Cancer Institute)
10.4.1. Therapy Overview
10.4.2. Current Development Status
10.4.3. Key Clinical Trial Results
10.4.4. Dosage Regimen and Manufacturing
 
11. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES
11.1. Chapter Overview
11.2. Hematological Malignancies
11.2.1. Leukemia and Lymphoma
11.2.1.1. Leukemia: Introduction and Epidemiology
11.2.1.1.1. Acute Myeloid Leukemia (AML)
11.2.1.1.2. Chronic Myeloid Leukemia (CML)
11.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
11.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
11.2.1.2. Lymphoma: Introduction and Epidemiology
11.2.1.3. Current Treatment Landscape
11.2.1.3.1. Targeted Therapies
11.2.1.4. T-Cell Immunotherapy and Affiliated Research Landscape
11.2.1.4.1. CAR-T Cell Therapies and Leukemia / Lymphoma
11.2.1.4.2. TCR-based Therapies and Leukemia / Lymphoma
11.2.1.4.3. TIL-based Therapies and Leukemia
 
11.2.2. Multiple Myeloma
11.2.2.1. Introduction and Epidemiology
11.2.2.2. Current Treatment Landscape
11.2.2.3. T-Cell Immunotherapy and Affiliated Research Landscape
 
11.3. Solid Tumors
11.3.1. Metastatic Melanoma
11.3.1.1. Introduction and Epidemiology
11.3.1.2. Current Treatment Landscape
11.3.1.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.1.3.1. CAR-T Cell Therapies and Metastatic Melanoma
11.3.1.3.2. TCR-based Therapies and Metastatic Melanoma
11.3.1.3.3. TIL-based Therapies and Metastatic Melanoma
 
11.3.2. Lung Cancer
11.3.2.1. Introduction and Epidemiology
11.3.2.2. Current Treatment Landscape
11.3.2.3. T-Cell Immunotherapy and Affiliated Research Landscape
 
11.3.3. Pancreatic Cancer
11.3.3.1. Introduction and Epidemiology
11.3.3.2. Current Treatment Landscape
11.3.3.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.3.3.1. CAR-T Cell Therapies and Pancreatic Cancer
11.3.3.3.2. TCR-based Therapies and Pancreatic Cancer
11.3.3.3.3. TIL-based Therapies and Pancreatic Cancer
 
11.3.4. Liver Cancer
11.3.4.1. Current Treatment Landscape
11.3.4.2. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.4.2.1. CAR-T Cell Therapies and Liver Cancer
11.3.4.2.2. TCR-based Therapies and Liver Cancer
11.3.4.2.3. TIL-based Therapies and Liver Cancer
 
11.3.5. Breast Cancer
11.3.5.1. Introduction and Epidemiology
11.3.5.2. Current Treatment Landscape
11.3.5.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.5.3.1. CAR-T Cell Therapies and Breast Cancer
11.3.5.3.2. TCR-based Therapies and Breast Cancer
11.3.5.3.3. TIL-based Therapies and Breast Cancer
 
11.3.6. Ovarian Cancer
11.3.6.1. Introduction and Epidemiology
11.3.6.2. Current Treatment Landscape
11.3.6.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.6.3.1. CAR-T Cell Therapies and Ovarian Cancer
11.3.6.3.2. TCR-based Therapies and Ovarian Cancer
11.3.6.3.3. TIL-based Therapies and Ovarian Cancer
 
11.3.7. Bladder Cancer
11.3.7.1. Introduction and Epidemiology
11.3.7.2. Current Treatment Landscape
11.3.7.3. T-Cell Immunotherapy and Affiliated Research Landscape
 
11.3.8. Kidney Cancer
11.3.8.1. Introduction and Epidemiology
11.3.8.2. Current Treatment Landscape
11.3.8.3. T-Cell Immunotherapy and Affiliated Research Landscape
 
12. EMERGING TECHNOLOGIES
12.1. Chapter Overview
12.2. Genome Editing Technologies
12.2.1. Technology Overviews
12.2.2. Applications
12.2.3. Emerging Technology Platforms Used in T-Cell Therapies
12.2.3.1. CRISPR / Cas9 System
12.2.3.1.1. Key Components and Function
12.2.3.1.2. Mechanism of Action
12.2.3.1.3. Targeting Efficiency and Challenges
12.2.3.1.4. Next-GEN CRISPR Technology
12.2.3.1.5. Technology Providers
12.2.3.1.5.1. Editas Medicine
12.2.3.1.5.2. Intellia Therapeutics
12.2.3.1.5.3. CRISPR Therapeutics
12.2.3.1.5.4. Beam Therapeutics
12.2.3.1.5.5. Gracell Biotechnologies
 
12.2.3.2. TALENs
12.2.3.2.1. Key Components and Function
12.2.3.2.2. Mechanism of Action
12.2.3.2.3. Advantages and Challenges
12.2.3.2.4. Technology Providers
12.2.3.2.4.1. Cellectis
12.2.3.2.4.2. Editas Medicine
 
12.2.3.3. megaTAL
12.2.3.3.1. Technology Providers
12.2.3.3.1.1. bluebird bio
 
12.2.3.4. Zinc Finger Nuclease
12.2.3.4.1. Technology Providers
12.2.3.4.1.1. Sangamo Therapeutics
12.2.4. Competitive Analysis: Gene Editing Platforms
 
12.3. Designing T-Cell Therapies with Improved Characteristics
12.3.1. Technologies for Targeting Multiple Cancers
12.3.1.1. Antibody Coupled T-Cell Receptor
12.3.1.1.1. Unum Therapeutics
12.3.1.2. NKR-T Platform
12.3.1.2.1. Celyad
12.3.1.2.2. Glycostem
 
12.3.2. Technologies for Improved Safety
12.3.2.1. Armored CAR and EGFRt Technology
12.3.2.1.1. Juno Therapeutics
12.3.2.2. RheoSwitch Therapeutic System
12.3.2.2.1. Intrexon
12.3.2.1. Inducible Caspase 9 Safety Switch
12.3.2.1.1. Bellicum Pharmaceuticals
12.3.2.1.1.1. CaspaCIDe Technology
12.3.2.1.1.2. CIDeCAR Technology
12.3.2.1.1.3. GoCAR-T Technology
12.3.2.2. On-Off Switch, Multiple Companies
12.3.2.2.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
12.3.2.2.2. On-Off Switch (Theravectys)
12.3.2.3. Other Technologies to Improve CAR-T Safety
 
12.3.3. Allogeneic Technologies
12.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
12.3.3.2. Allogeneic Platform (Celyad)
12.3.3.3. Allogeneic Platform (Cellectis)
 
13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. T-Cell Immunotherapies Market: Partnerships and Collaborations
13.3.1. Analysis by Year of Partnerships
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Type of Partnership and Type of Product
13.3.4. Analysis by Type of Industry and Type of Product
13.3.5. Analysis by Individual Products
13.3.6. Most Active Industry Players: Analysis by Number of Partnerships
13.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
13.3.8. Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements
13.3.9. Regional Analysis
13.3.10. Intercontinental and Intracontinental Agreements
 
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
14.3.1. Analysis by Number of Funding Instances
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Amount Invested across Different Type of Therapies
14.3.5. Most Active Players: Analysis by Number of Instances
14.3.6. Analysis by Amount Invested by Different Type of Investors
14.3.7. Most Active Investors: Analysis by Number of Instances
14.3.8. Regional Analysis by Amount Invested
 
15. OTHER T-CELL IMMUNOTHERAPIES
15.1. Chapter Overview
15.2. Other T-Cell Immunotherapies
15.2.1. Analysis by Phase of Development
15.2.2. Analysis by Target Therapeutic Area
15.2.3. Analysis by Type of Cells
15.2.4. Analysis by Source of T-Cells
15.3. Treg Cell Therapy
15.3.1. Caladrius Biosciences
15.3.2. TRACT Therapeutics
15.3.3. Cellenkos
15.3.4. Other Companies
 
15.4. T-Cell-based Vaccines
15.4.1. Immunovative Therapies
15.4.2. TVAX Biomedical
 
15.5. Virus-Driven T-Cell Therapy
15.5.1. Atara Biotherapeutics
15.5.2. bluebird bio
15.5.3. Cell Medica
15.5.4. Eutilex
15.5.5. Tessa Therapeutics
15.5.6. ViGenCell
 
15.6. Fucosylated T-Cell Therapy
15.6.1. Targazyme
 
15.7. PD-1 Knockout Engineered T-Cell Therapy
15.7.1. Chengdu MedGenCell
15.7.2. Anhui Kedgene Biotechnology
 
15.8. TAC-T Cell Therapy
15.8.1. Triumvira Immunologics
 
15.9. Gama Delta T-Cell Therapy
15.9.1. GammaCell Bio-Technologies
15.9.2. TC Biopharm
 
16. CASE STUDY: CELL THERAPY MANUFACTURING
16.1. Chapter Overview
16.2. An Overview to Cell Therapy Manufacturing
16.3. Cell Therapy Manufacturing Models
16.3.1. Centralized Manufacturing Model
16.3.2. Decentralized Manufacturing Model
16.4. Scalability of Cell Therapy Manufacturing Processes
16.4.1. Scale-Up
16.4.2. Scale-out
16.5. Types of Cell Therapy Manufacturers
16.6. Key Challenges Related to Manufacturing Cell Therapies
16.7. Important Factors for Cell Therapy Manufacturing
16.7.1. Characterization
16.7.2. Cost of Goods
16.8. Automation of Cell Therapy Manufacturing Processes
16.9. Cell Therapy Manufacturing Supply Chain
16.10. Companies with In-House Capabilities
16.11. Contract Manufacturers
16.12. Regulatory Landscape
 
17. COST PRICE ANALYSIS
17.1. Chapter Overview
17.2. Factors Contributing to the High Price of Cell / Gene Therapies
17.3. Pricing Models for T-Cell Immunotherapies
17.3.1. Based on Associated Costs
17.3.2. Based on Availability of Competing Products
17.3.3. Based on Patient Segment
17.3.4. Based on the Opinions of Industry Experts
17.4. Reimbursement-related Considerations For T-Cell Immunotherapies
17.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies
 
18. MARKET SIZING AND OPPORTUNITY ANALYSIS
18.1. Chapter Overview
18.2. Scope and Limitations
18.3. Key Assumptions and Forecast Methodology
18.4. Overall T-Cell Immunotherapy Market, 2019-2030
18.4.1. T-Cell Immunotherapy Market: Distribution by Type of Therapy
18.4.2. T-Cell Immunotherapy Market: Distribution by Target Indications
18.4.3. T-Cell Immunotherapy Market: Distribution by Target Antigen
18.4.4. T-Cell Immunotherapy Market: Key Players
18.4.5. T-Cell Immunotherapy Market: Distribution by Geography
18.5. T-Cell Immunotherapy Market: Value Creation Analysis
 
18.6. Overall CAR-T Cell Therapies Market, 2019-2030
18.6.1. CAR-T Cell Therapies Market: Distribution by Target Indication
18.6.2. CAR-T Cell Therapies Market: Distribution by Target Antigen
18.6.3. CAR-T Cell Therapies Market: Key Players
18.6.4. CAR-T Cell Therapies Market: Distribution by Geography
 
18.6.5. Product Wise Sales Forecast
18.6.5.1. KYMRIAH® (Novartis)
18.6.5.1.1. Target Patient Population
18.6.5.1.2. Sales Forecast (USD Million)
18.6.5.1.3. Net Present Value
18.6.5.1.4. Value Creation Analysis
 
18.6.5.2. YESCARTA® (Gilead Sciences)
18.6.5.2.1. Target Patient Population
18.6.5.2.2. Sales Forecast (USD Million)
18.6.5.2.3. Net Present Value (USD Million)
18.6.5.2.4. Value Creation Analysis
18.6.5.3. bb2121 (bluebird bio / Celgene)
18.6.5.3.1. Target Patient Population
18.6.5.3.2. Sales Forecast (USD Million)
18.6.5.3.3. Net Present Value (USD Million)
18.6.5.3.4. Value Creation Analysis
 
18.6.5.4. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
18.6.5.4.1. Target Patient Population
18.6.5.4.2. Sales Forecast (USD Million)
18.6.5.4.3. Net Present Value (USD Million)
18.6.5.4.4. Value Creation Analysis
 
18.6.5.5. MB-CART19.1 (Miltenyi Biotec)
18.6.5.5.1. Target Patient Population
18.6.5.5.2. Sales Forecast (USD Million)
18.6.5.5.3. Net Present Value (USD Million)
18.6.5.5.4. Value Creation Analysis
 
18.6.5.6. CD19 CAR-T (Sinobioway Cell Therapy)
18.6.5.6.1. Target Patient Population
18.6.5.6.2. Sales Forecast (USD Million)
18.6.5.6.3. Net Present Value (USD Million)
18.6.5.6.4. Value Creation Analysis
 
18.6.5.7. JCAR017 (Juno Therapeutics / Celgene / Wuxi AppTec)
18.6.5.7.1. Target Patient Population
18.6.5.7.2. Sales Forecast (USD Million)
18.6.5.7.3. Net Present Value (USD Million)
18.6.5.7.4. Value Creation Analysis
 
18.6.5.8. AUTO2 (Autolus)
18.6.5.8.1. Target Patient Population
18.6.5.8.2. Sales Forecast (USD Million)
18.6.5.8.3. Net Present Value (USD Million)
18.6.5.8.4. Value Creation Analysis
18.6.5.9. AUTO3 (Autolus)
18.6.5.9.1. Target Patient Population
18.6.5.9.2. Sales Forecast (USD Million)
18.6.5.9.3. Net Present Value (USD Million)
18.6.5.9.4. Value Creation Analysis
 
18.6.5.10. GPC3 CAR-T (Shanghai GeneChem)
18.6.5.10.1. Target Patient Population
18.6.5.10.2. Sales Forecast (USD Million)
18.6.5.10.3. Net Present Value (USD Million)
18.6.5.10.4. Value Creation Analysis
 
18.6.5.11. BCMA CAR-T (The Pregene ShenZhen Biotechnology)
18.6.5.11.1. Target Patient Population
18.6.5.11.2. Sales Forecast (USD Million)
18.6.5.11.3. Net Present Value (USD Million)
18.6.5.11.4. Value Creation Analysis
 
18.6.5.12. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
18.6.5.12.1. Target Patient Population
18.6.5.12.2. Sales Forecast (USD Million)
18.6.5.12.3. Net Present Value (USD Million)
18.6.5.12.4. Value Creation Analysis
 
18.6.5.13. CD19 CAR-T (Shanghai Bioray Laboratory)
18.6.5.13.1. Target Patient Population
18.6.5.13.2. Sales Forecast (USD Million)
18.6.5.13.3. Net Present Value (USD Million)
18.6.5.13.4. Value Creation Analysis
 
18.6.5.14. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
18.6.5.14.1. Target Patient Population
18.6.5.14.2. Sales Forecast (USD Million)
18.6.5.14.3. Net Present Value (USD Million)
18.6.5.14.4. Value Creation Analysis
18.6.5.15. PCAR-019 (PersonGen BioTherapeutics)
18.6.5.15.1. Target Patient Population
18.6.5.15.2. Sales Forecast (USD Million)
18.6.5.15.3. Net Present Value (USD Million)
18.6.5.15.4. Value Creation Analysis
 
18.6.5.16. TBI-1501 (Takara Bio)
18.6.5.16.1. Target Patient Population
18.6.5.16.2. Sales Forecast (USD Million)
18.6.5.16.3. Net Present Value (USD Million)
18.6.5.16.4. Value Creation Analysis
 
18.6.5.17. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
18.6.5.17.1. Target Population
18.6.5.17.2. Sales Forecast (USD Million)
18.6.5.17.3. Net Present Value (USD Million)
18.6.5.17.4. Value Creation Analysis
 
18.6.5.18. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
18.6.5.18.1. Target Patient Population
18.6.5.18.2. Sales Forecast (USD Million)
18.6.5.18.3. Net Present Value (USD Million)
18.6.5.18.4. Value Creation Analysis
 
18.6.5.19. BinD19 (Shenzhen BinDeBio)
18.6.5.19.1. Target Patient Population
18.6.5.19.2. Sales Forecast (USD Million)
18.6.5.19.3. Net Present Value (USD Million)
18.6.5.19.4. Value Creation Analysis
 
18.6.5.20. CARCIK-CD19 (Formula Pharmaceuticals)
18.6.5.20.1. Target Patient Population
18.6.5.20.2. Sales Forecast (USD Million)
18.6.5.20.3. Net Present Value (USD Million)
18.6.5.20.4. Value Creation Analysis
18.6.5.21. EGFR CART Cell Therapy (The Beijing Pregene Science and Technology)
18.6.5.21.1. Target Patient Population
18.6.5.21.2. Sales Forecast (USD Million)
18.6.5.21.3. Net Present Value (USD Million)
18.6.5.21.4. Value Creation Analysis
 
18.6.5.22. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
18.6.5.22.1. Target Patient Population
18.6.5.22.2. Sales Forecast (USD Million)
18.6.5.22.3. Net Present Value (USD Million)
18.6.5.22.4. Value Creation Analysis
 
18.7. Overall TCR-based Therapies Market
18.7.1. TCR-Based Therapies Market: Distribution by Target Indication
18.7.2. TCR-Based Therapies Market: Distribution by Target Antigen
18.7.3. TCR-Based Therapies Market:  Key Players
18.7.4. TCR-Based Therapies Market: Distribution by Geography
 
18.7.5. Product Wise Sales Forecast
18.7.5.1. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck)
18.7.5.1.1. Target Patient Population
18.7.5.1.2. Sales Forecast (USD Million)
18.7.5.1.3. Net Present Value (USD Million)
18.7.5.1.4. Value Creation Analysis
 
18.7.5.2. IMCgp100 (Immunocore)
18.7.5.2.1. Target Patient Population
18.7.5.2.2. Sales Forecast (USD Million)
18.7.5.2.3. Net Present Value (USD Million)
18.7.5.2.4. Value Creation Analysis
 
18.7.5.3. TBI-1301 (Takara Bio)
18.7.5.3.1. Target Patient Population
18.7.5.3.2. Sales Forecast (USD Million)
18.7.5.3.3. Net Present Value (USD Million)
18.7.5.3.4. Value Creation Analysis
 
18.7.5.4. ALT 801 (Altor BioScience)
18.7.5.4.1. Target Patient Population
18.7.5.4.2. Sales Forecast (USD Million)
18.7.5.4.3. Net Present Value (USD Million)
18.7.5.4.4. Value Creation Analysis
 
18.7.5.5. JTCR016 (Juno Therapeutics)
18.7.5.5.1. Target Patient Population
18.7.5.5.2. Sales Forecast (USD Million)
18.7.5.5.3. Net Present Value (USD Million)
18.7.5.5.4. Value Creation Analysis
 
18.7.5.6. LioCyx (Lion TCR)
18.7.5.6.1. Target Patient Population
18.7.5.6.2. Sales Forecast (USD Million)
18.7.5.6.3. Net Present Value (USD Million)
18.7.5.6.4. Value Creation Analysis
 
18.7.5.7. YT-E001 (China Immunotech)
18.7.5.7.1. Target Patient Population
18.7.5.7.2. Sales Forecast (USD Million)
18.7.5.7.3. Net Present Value (USD Million)
18.7.5.7.4. Value Creation Analysis
 
18.8. Overall TIL-Based Therapies Market
18.8.1. TIL-Based Therapies Market: Distribution by Target Indication
18.8.2. TIL-Based Therapies Market:  Key Players
18.8.3. TIL-Based Therapies Market: Distribution by Geography
 
18.8.4. Product Wise Sales Forecast
18.8.4.1. TILs (Nantes University Hospital)
18.8.4.1.1. Target Patient Population
18.8.4.1.2. Sales Forecast (USD Million)
18.8.4.1.3. Net Present Value (USD Million)
18.8.4.1.4. Value Creation Analysis
 
18.8.4.2. TILs (Netherlands Cancer Institute)
18.8.4.2.1. Target Patient Population
18.8.4.2.2. Sales Forecast (USD Million)
18.8.4.2.3. Net Present Value (USD Million)
18.8.4.2.4. Value Creation Analysis
 
18.8.4.3. Lifileucel (LN-144) (Iovance Biotherapeutics)
18.8.4.3.1. Target Patient Population
18.8.4.3.2. Sales Forecast (USD Million)
18.8.4.3.3. Net Present Value (USD Million)
18.8.4.3.4. Value Creation Analysis
 
18.8.4.4. LN-145 (Iovance Biotherapeutics)
18.8.4.4.1. Target Patient Population
18.8.4.4.2. Sales Forecast (USD Million)
18.8.4.4.3. Net Present Value (USD Million)
18.8.4.4.4. Value Creation Analysis
 
18.8.4.5. LTX-315 and TILs (Lytix Biopharma)
18.8.4.5.1. Target Patient Population
18.8.4.5.2. Sales Forecast (USD Million)
18.8.4.5.3. Net Present Value (USD Million)
18.8.4.5.4. Value Creation Analysis
 
19. PROMOTIONAL ANALYSIS
19.1. Chapter Overview
19.2. Channels used for Promotional Campaigns
19.3. Summary of Product Website Analysis
19.4. Summary of Patient Support Services and Informative Downloads
 
19.5. KYMRIAH®: Promotional Analysis
19.5.1. Drug Overview
19.5.2. Product Website Analysis
19.5.2.1. Messages for Healthcare Professionals
19.5.2.2. Messages for Patients
19.5.3. Patient Support Services and Informative Downloads
19.5.4. Other Promotional Activities
19.5.4.1. Presence in Conferences
 
19.6. YESCARTA®: Promotional Analysis
19.6.1. Drug Overview
19.6.2. Product Website Analysis
19.6.2.1. Messages for Healthcare Professionals
19.6.2.2. Messages for Patients
19.6.3. Patient Support Services and Informative Downloads
19.6.4. Other Promotional Activities
19.6.4.1. Presence in Conferences
 
20. COMPANY PROFILES
20.1. Chapter Overview
20.2. Adaptimmune Therapeutics
20.3. Autolus
20.4. bluebird bio
20.5. CARsgen Therapeutics
20.6. Celgene
20.7. Cell Medica
20.8. Cellectis
20.9. Cellular Biomedicine Group
20.10. Immunocore
20.11. Innovative Cellular Therapeutics
20.12. Iovance Biotherapeutics
20.13. Kite Pharma
20.14. Lion TCR 
20.15. Noile-Immune Biotech
20.16. Novartis
20.17. Shanghai GeneChem
20.18. Sinobioway Cell Therapy
20.19. Takara Bio
20.20. Unum Therapeutics
20.21. ZIOPHARM Oncology
 
21. CONCLUDING REMARKS
21.1. Chapter Overview
21.2. Key Takeaways
 
22. EXECUTIVE INSIGHTS
22.1. Chapter Overview
22.2. Cell Therapies
22.2.1 Interview Transcript: Tim Oldham, Chief Executive Officer 
22.4. Gracell Biotechnologies 
22.4.1 Interview Transcript: Wei (William) Cao, Chief Executive Officer
22.5. Lion TCR
22.5.1 Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
22.6. TxCell
22.6.1 Interview Transcript: Miguel Forte, Chief Operating Officer
22.7. Kite Pharma
22.7.1 Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
22.8. Celyad
22.8.1 Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys 
22.9. Iovance Biotherapeutics
22.9.1 Interview Transcript: Peter Ho, Director, Process Development
22.10. Waisman Biomanufacturing
22.10.1 Interview Transcript: Brian Dattilo, Manager of Business Development
22.11. Theravectys
22.11.1 Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
22.12. Changhai Hospital
22.12.1 Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
22.13. University of Colorado
22.13.1 Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine
 
23. APPENDIX 1: TABULATED DATA
 
24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1. Pillars of Cancer Therapy
Figure 3.2. Differences between Active and Passive Immunotherapies
Figure 3.3. Differences between Specific and Non-Specific Immunotherapies
Figure 3.4. Strategies Employed for the Redirection of T-Cells
Figure 3.5. T-Cell Manufacturing: General Procedure
Figure 3.6. Historical Development of CAR-T cells
Figure 3.7. Structure of Chimeric Antigen Receptor
Figure 3.8. Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9. CAR-T Cell Therapies: Development Process
Figure 3.10. Challenges Associated with CAR-T Cell Therapies
Figure 3.11. TCR-based Therapies: Development Process
Figure 3.12. TIL-based Therapies: Development Process
Figure 3.13. T-Cell Immunotherapies: Benefits and Key Challenges
Figure 4.1. Social Media Analysis: Historical Trend on Twitter, January 2012-April 2019
Figure 4.2. Social Media Analysis: Trending Words / Phrases on Twitter
Figure 4.3. Social Media Analysis: Most Popular Drug Candidates on Twitter
Figure 4.4. Social Media Analysis: Most Prolific Authors on Twitter
Figure 4.5. Average Number of Likes, Re-tweets and Comments Related to T-cell Immunotherapy
Figure 4.6. Social Media Analysis: Most Popular Indications and Target Antigen
Figure 5.1. T-Cell Immunotherapies: Analysis by Type of Product
Figure 5.2. T-Cell Immunotherapies: Analysis by Type of Developer
Figure 5.3. T-Cell Immunotherapies: Analysis by Type of Developer and Type of Product
Figure 5.4. T-Cell Immunotherapies: Analysis by Phase of Development
Figure 5.5. T-Cell Immunotherapies: Analysis by Phase of Development and Type of Product
Figure 5.6. T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Figure 5.7. T-Cell Immunotherapies: Analysis by Target Therapeutic Area and Type of Product
Figure 5.8. T-Cell Immunotherapies: Analysis by Popular Target Indications
Figure 5.9. CAR-T Cell Immunotherapies: Analysis by Popular Target Indications
Figure 5.10. TCR-based Immunotherapies: Analysis by Popular Target Indications
Figure 5.11. TIL-based Immunotherapies: Analysis by Popular Target Indications
Figure 5.12. CAR-T Cell Immunotherapies: Analysis by Target Antigen
Figure 5.13. TCR-based Immunotherapies: Analysis by Target Antigen
Figure 5.14. T-Cell Immunotherapies: Analysis by Source of T-Cells
Figure 5.15. T-Cell Immunotherapies: Analysis by Source of T-Cells and Type of Product
Figure 5.16. T-Cell Immunotherapies: Analysis by Route of Administration
Figure 5.17. T-Cell Immunotherapies: Analysis by Route of Administration and Type of Product
Figure 5.18. T-Cell Immunotherapies: Analysis by Patient Segment
Figure 5.19. T-Cell Immunotherapies: Analysis by Patient Segment and Type of Product
Figure 5.20. T-Cell Immunotherapies: Analysis by Type of Therapy
Figure 5.21. T-Cell Immunotherapies: Analysis by Type of Therapy and Type of Product
Figure 5.22. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 5.23. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 5.24. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Figure 5.25. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Figure 6.1. T-Cell Immunotherapies: Popular Targets in Hematological Malignancies
Figure 6.2. T-Cell Immunotherapies: Popular Targets in Solid Tumor
Figure 6.3. CAR-T Cell Immunotherapies: Geographical Distribution of Key Opinion Leaders
Figure 6.4. CAR-T Cell Immunotherapies: Prominent Key Opinion Leaders
Figure 6.5. TCR-based Immunotherapies: Geographical Distribution of Key Opinion Leaders
Figure 6.6. TCR-based Immunotherapies: Prominent Key Opinion Leaders
Figure 6.7. TIL-based Immunotherapies: Geographical Distribution of Key Opinion Leaders
Figure 6.8. TIL-based Immunotherapies: Prominent Key Opinion Leaders
Figure 6.9. CAR-Construction: Analysis by Generation of CAR-T Therapies
Figure 6.10. CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
Figure 6.11. CAR-Construction: Analysis by Type of Vector
Figure 6.12.  CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Figure 7.1. CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.2. CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2016-2019)
Figure 8.1. Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 10.1. Nantes University Hospital’s TIL Therapy: Production Procedure
Figure 11.1. Leukemia: Classification
Figure 11.2. Leukemia: Global Epidemiological Distribution
Figure 11.3. Lymphoma: Global Epidemiological Distribution
Figure 11.4. Multiple Myeloma: Global Epidemiological Distribution
Figure 11.5. Melanoma: Global Epidemiological Distribution
Figure 11.6. Lung Cancers: Classification
Figure 11.7. Lung Cancer: Global Epidemiological Distribution
Figure 11.8. Pancreatic Cancer: Global Epidemiological Distribution
Figure 11.9. Liver Cancer: Global Epidemiological Distribution
Figure 11.10. Breast Cancer: Global Epidemiological Distribution
Figure 11.11. Ovarian Cancer: Global Epidemiological Distribution
Figure 11.12. Bladder Cancer: Global Epidemiological Distribution
Figure 11.13. Kidney Cancer: Global Epidemiological Distribution
Figure 12.1. Genome Editing Technologies: Applications
Figure 12.2. Genome Editing: Emerging Technology Platforms used in T-Cell Therapies
Figure 12.3. Competitiveness Analysis: Gene Editing Platforms
Figure 12.4. T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
Figure 12.5. Cellectis: Properties of Enhanced T-Cell Platform
Figure 12.6. Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 13.1. Partnerships and Collaborations: Cumulative Trend by Year, 2005-2019
Figure 13.2. Partnerships and Collaborations: Year-Wise Trend of Industry vs Non-Industry Partnerships, 2005-2019
Figure 13.3. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.4. Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2016 and 2016-2019
Figure 13.5. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 13.6. Partnerships and Collaborations: Distribution by Type of Product and Year-Wise Trend
Figure 13.7. Partnerships and Collaborations: Distribution by Type of Industry
Figure 13.8. Partnerships and Collaborations: Distribution by Type of Industry and Type of Product
Figure 13.9. Partnerships and Collaborations: Distribution by Individual Products
Figure 13.10. Partnerships and Collaborations: Most Active Industry Players
Figure 13.11. Partnerships and Collaborations: Most Active Non-Industry Players
Figure 13.12. Partnerships and Collaborations: Most Active Contract Manufacturers
Figure 13.13. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution of Manufacturing Agreements
Figure 13.14. Partnerships and Collaborations: Regional Distribution
Figure 13.15. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 14.1. Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre 2012-2019
Figure 14.2. Funding and Investment Analysis: Cumulative Amount Invested, Pre 2012-2019 (USD Million)
Figure 14.3. Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre 2012-2019
Figure 14.4. Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, Pre 2012-2019 (USD Million)
Figure 14.5. Funding and Investments: Analysis by Amount Invested across Different Types of Products
Figure 14.6. Most Active Players: Distribution by Number of Instances
Figure 14.7. Funding and Investments: Analysis by Amount Invested across Different Types of Investors
Figure 14.8. Most Active Investors: Distribution by Number of Instances
Figure 14.9. Funding and Investment Analysis: Distribution by Geography
Figure 14.10. Funding and Investment Analysis: Analysis by Amount Invested across Different Countries (USD Million)
Figure 15.1. Other T-Cell Immunotherapies: Analysis by Phase of Development
Figure 15.2. Other T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Figure 15.3. Other T-Cell Immunotherapies: Analysis by Type of T-Cells
Figure 15.4. Other T-Cell Immunotherapies: Analysis by Source of T-Cells
Figure 15.5. Treg Cells: Functions
Figure 16.1. Steps for Manufacturing Cell Therapies
Figure 16.2. Centralized Manufacturing: Process Model
Figure 16.3. Decentralized Manufacturing: Process Model
Figure 16.4. Cell Therapy Manufacturing: Types of Manufacturers
Figure 16.5. Cell Therapy: Challenges and Drivers
Figure 16.6. Cell Therapies: Potency as Critical Quality Attribute
Figure 16.7. Cell Therapy Manufacturing: Supply Chain Model
Figure 16.8. Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 17.1. Targeted Therapies: Pricing Model Based on Patient Segment
Figure 18.1. Overall T-Cell Immunotherapy Market, 2019-2030 (USD Billion)
Figure 18.2. T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2030 (USD Billion)
Figure 18.3. T-Cell Immunotherapy Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Figure 18.4. T-Cell Immunotherapy Market: Distribution by Target Antigens(s), 2025 and 2030 (USD Billion)
Figure 18.5. T-Cell Immunotherapy Market:  Key Players, 2025 and 2030 (USD Billion)
Figure 18.6. T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Figure 18.7. Overall CAR-T Cell Therapies Market, 2019-2030 (USD Billion)
Figure 18.8. CAR-T Cell Therapies Market: Distribution by Target Indication(s) (USD Billion)
Figure 18.9. CAR-T Cell Therapies Market: Distribution by Target Antigen(s) (USD Billion)
Figure 18.10. CAR-T Cell Therapies Market:  Key Players (USD Billion)
Figure 18.11. CAR-T Cell Therapies Market: Distribution by Geography (USD Billion)
Figure 18.12. KYMRIAH® (Novartis): Current Status of Development
Figure 18.13. KYMRIAH® (Novartis) Sales Forecast, till 2030 (USD Million)
Figure 18.14. YESCARTA® (Gilead Sciences): Current Status of Development
Figure 18.15. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
Figure 18.16. bb2121 (bluebird bio / Celgene): Current Status of Development
Figure 18.17. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030 (USD Million)
Figure 18.18. LCAR-B38M CAR-T (Nanjing Legend Biotech /Janssen): Current Status of Development
Figure 18.19. LCAR-B38M CAR-T (Nanjing Legend Biotech /Janssen) Sales Forecast, till 2030 (USD Million)
Figure 18.20. MB-CART19.1 (Miltenyi Biotec): Current Status of Development
Figure 18.21. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030 (USD Million)
Figure 18.22. CD19 CAR-T (Sinobioway Cell Therapy): Current Status of Development
Figure 18.23. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030 (USD Million)
Figure 18.24. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Current Status of Development
Figure 18.25. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030 (USD Million)
Figure 18.26. AUTO2 (Autolus): Current Status of Development
Figure 18.27. AUTO2 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 18.28. AUTO3 (Autolus): Current Status of Development
Figure 18.29. AUTO3 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 18.30. GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
Figure 18.31. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030 (USD Million)
Figure 18.32. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 18.33. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 18.34. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 18.35. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 18.36. CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
Figure 18.37. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030 (USD Million)
Figure 18.38.  Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Current Status of Development
Figure 18.39. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology, till 2030 (USD Million)
Figure 18.40. PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
Figure 18.41. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.42. TBI-1501 (Takara Bio): Current Status of Development
Figure 18.43. TBI-1501 (Takara Bio) Sales Forecast, till 2030 (USD Million)
Figure 18.44. IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
Figure 18.45. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.46. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Current Status of Development
Figure 18.47. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030 (USD Million)
Figure 18.48. BinD19 (Shenzhen BinDeBio): Current Status of Development
Figure 18.49. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030 (USD Million)
Figure 18.50. CARCIK-CD19 (Formula Pharmaceuticals): Current Status of Development
Figure 18.51. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030 (USD Million)
Figure 18.52. EGFR CART (The Beijing Pregene Science and Technology): Current Status of Development
Figure 18.53. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.54. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Current Status of Development
Figure 18.55. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.56. Overall TCR-based Therapies Market, 2019-2030 (USD Billion)
Figure 18.57. TCR-Based Therapies Market: Distribution by Target Indication(s) (USD Billion)
Figure 18.58. TCR-Based Therapies Market: Distribution by Target Antigen(s) (USD Billion)
Figure 18.59. TCR-Based Therapies Market:  Key Players (USD Billion)
Figure 18.60. TCR-Based Therapies Market: Distribution by Geography (USD Billion)
Figure 18.61. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Current Status of Development
Figure 18.62. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030 (USD Million)
Figure 18.63. IMCgp100 (Immunocore): Current Status of Development
Figure 18.64. IMCgp100 (Immunocore) Sales Forecast, till 2030 (USD Million)
Figure 18.65. TBI-1301 (Takara Bio): Current Status of Development
Figure 18.66. TBI-1301 (Takara Bio) Sales Forecast, till 2030 (USD Million)
Figure 18.67. ALT 801 (Altor BioScience): Current Status of Development
Figure 18.68. ALT 801 (Altor BioScience) Sales Forecast, till 2030 (USD Million)
Figure 18.69. JTCR016 (Juno Therapeutics): Current Status of Development
Figure 18.70. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.71. LioCyx (Lion TCR): Current Status of Development
Figure 18.72. LioCyx (Lion TCR) Sales Forecast, till 2030 (USD Million)
Figure 18.73. YT-E001 (China Immunotech): Current Status of Development
Figure 18.74. YT-E001 (China Immunotech) Sales Forecast, till 2030 (USD Million)
Figure 18.75. Overall TIL-based Therapies Market, 2019-2030 (USD Billion)
Figure 18.76. TIL-Based Therapies Market: Distribution by Target Indication(s) (USD Billion)
Figure 18.77. TIL-Based Therapies Market:  Key Players (USD Billion)
Figure 18.78. TIL-Based Therapies Market: Distribution by Geography (USD Billion)
Figure 18.79. TILs (Nantes University Hospital): Current Status of Development
Figure 18.80. TILs (Nantes University Hospital) Sales Forecast, till 2030) (USD Million)
Figure 18.81. TILs (Netherland Cancer Institute): Current Status of Development
Figure 18.82. TILs (Netherland Cancer Institute) Sales Forecast, till 2030 (USD Million)
Figure 18.83. Lifileucel (LN-144) (Iovance Biotherapeutics): Current Status of Development
Figure 18.84. Lifileucel (LN-144) Sales Forecast, till 2030 (USD Million)
Figure 18.85. LN-145 (Iovance Biotherapeutics): Current Status of Development
Figure 18.86. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.87. LTX-315 and TILs (Lytix Biopharma): Current Status of Development
Figure 18.88. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030 (USD Million)
Figure 19.1. Channels Used for Promotional Campaigns
Figure 19.2. Promotional / Marketing Strategy: Product Website Analysis
Figure 19.3. Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Figure 19.4. Product Website Analysis: KYMRIAH®, Messages for Healthcare Professionals
Figure 19.5. Product Website Analysis: KYMRIAH®, Messages for Patients
Figure 19.6. Product Website Analysis: KYMRIAH®, Patient Support Program
Figure 19.7. KYMRIAH®, Presence in Conferences
Figure 19.8. Product Website Analysis: YESCARTA®, Messages for Healthcare Professionals
Figure 19.9. Product Website Analysis: YESCARTA®, Messages for Patients
Figure 19.10. Product Website Analysis: YESCARTA®, Kite Konnect
Figure 19.11. Product Website Analysis: YESCARTA®, Platform for Reporting Adverse Events / Products Complaints and Requesting Medical Information
Figure 19.12. YESCARTA®, Presence in Conferences
Figure 21.1. T-Cell Immunotherapy Market Landscape: Industry Participants
Figure 21.2. T-Cell Immunotherapy Market Landscape: Non-Industry Participants
Figure 21.3. T-Cell Immunotherapy Market Forecast, 2019, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

List of Tables

Table 3.1. Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2. FDA Approved Antibody based Cancer Therapeutics
Table 3.5. Key Characteristics of CAR-T Cells
Table 3.6. Comparison of First and Second-Generation CAR-Ts
Table 3.7. CD19 CAR-T Cells: Preclinical Results
Table 3.8. Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 3.9. CAR-T Cell and TCR-based Therapies: Key Differences
Table 5.1. T-Cell Immunotherapies: Clinical Pipeline
Table 5.2. T-Cell Immunotherapy: Preclinical Pipeline
Table 6.1. CD19 CAR-T Cell Therapies: Competitive Landscape
Table 6.2. CD19 CAR-T Cell Therapies: Clinical Outcomes
Table 6.3. BCMA CAR-T Cell Therapies: Competitive Landscape
Table 6.4. BCMA CAR-T Cell Therapies: Clinical Outcomes
Table 6.5. Meso CAR-T Cell Therapies: Competitive Landscape
Table 6.6. Meso CAR-T Cell Therapies: Clinical Outcomes
Table 6.7. GD2 CAR-T Cell Therapies: Competitive Landscape
Table 6.8. GD2 CAR-T Cell Therapies: Clinical Outcomes
Table 6.9. CAR-T Cell Immunotherapies: Principle Investigators
Table 6.10. TCR-based Immunotherapies: Principle Investigators
Table 6.11. TIL-based Immunotherapies: Principle Investigators
Table 6.12. CAR-T Therapies: Information on Constructs of Clinical Candidates 
Table 7.1. CAR-T Cell Immunotherapies: List of Clinical Trials
Table 7.2. Advanced Phase CAR-T Cell Therapies in China
Table 8.1. KYMRIAH®: Clinical Studies
Table 8.2. KYMRIAH®: Clinical Trial Endpoints (ALL)
Table 8.3. KYMRIAH®: Clinical Trial Endpoints (CLL / MM / NHL / FL)
Table 8.4. YESCARTA®: Clinical Studies
Table 8.5. YESCARTA®: Clinical Trial Endpoints
Table 8.6. JCAR Series: Molecules in Clinical Development
Table 8.7. JCAR: CAR-T Design
Table 8.8. JCAR014: Clinical Studies
Table 8.9. JCAR017: Clinical Studies
Table 8.10. JCAR018: Clinical Studies
Table 8.11. JCAR020: Clinical Studies
Table 8.12. JCAR023: Clinical Studies
Table 8.13. JCAR024: Clinical Studies
Table 8.14. JCARH125: Clinical Studies
Table 8.15. JCAR Series: Clinical Trial Endpoints (Phase I/II / Phase II / Phase III)
Table 8.16. JCAR Series: Clinical Trial Endpoints (Phase I)
Table 8.17. JCAR: Dosage Regimen
Table 8.18. bb2121: Clinical Studies
Table 8.19. bb2121: Clinical Trial Endpoints
Table 8.20. LCAR-B38M CAR-T: Clinical Studies
Table 8.21. LCAR-B38M CAR-T: Clinical Trial Endpoints
Table 8.22. Takara Bio’s CD19 CAR-T: Clinical Studies
Table 8.23. Takara Bio’s CD19 CAR-T: Clinical Trial Endpoints
Table 8.24. TBI-1501: Dosage Regimen
Table 8.25. AUTO2: Clinical Studies
Table 8.26. AUTO3: Clinical Studies
Table 8.27. Autolus’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.28. Sinobioway Cell Therapy’s CD19 CAR-T Therapy: Clinical Studies
Table 8.29. Sinobioway Cell Therapy’s EPCAM CAR-T Therapy: Clinical Studies
Table 8.30. Sinobioway Cell Therapy’s Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.31. Phase I/II or Phase II CAR-T Cell Therapies from the Industry Players
Table 9.1. NY-ESO TCR: Clinical Studies
Table 9.2. MAGE-A10: Clinical Studies
Table 9.3. MAGE A-4: Clinical Studies
Table 9.4. AFP T-Cell: Clinical Studies
Table 9.5. NY-ESO TCR: Clinical Trial Endpoints
Table 9.6. MAGE A-10 / MAGE A-4 / AFP TCR: Clinical Trial Endpoints
Table 9.7. IMCgp100: Clinical Studies
Table 9.8. IMCgp100: Clinical Trial Endpoints
Table 9.9. ALT-801: Clinical Studies
Table 9.10. ALT-801: Clinical Trial Endpoints
Table 9.11. JTCR016: Clinical Studies
Table 9.12. JTCR016: Clinical Trial Endpoints
Table 9.13. WT1 TCR: Clinical Studies
Table 9.14. WT1 TCR: Clinical Trial Endpoints
Table 9.15. TBI-1301: Current Status of Development
Table 9.16. TBI-1301: Clinical Trial Endpoints
Table 10.1. LN-144: Clinical Studies
Table 10.2. LN-144: Clinical Trial Endpoints
Table 10.3. LN-145: Current Status of Development
Table 10.4. LN-145: Clinical Trial Endpoints
Table 10.5. LN-144: Patent Portfolio
Table 10.6. Nantes University Hospital’s TIL Therapy: Clinical Trial Endpoints
Table 10.7. Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Endpoints
Table 11.1. Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 11.2. Leukemia: List of Marketed Targeted Therapeutics
Table 11.3. Lymphoma: List of Marketed Targeted Therapeutics 
Table 11.4. T-Cell Immunotherapies: Targets under Investigation for Leukemia
Table 11.5. T-Cell Immunotherapies: Targets under Investigation for Lymphoma
Table 11.6. Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 11.7. T-Cell Immunotherapies: Targets under Investigation for Multiple Myeloma
Table 11.8. Melanoma: List of Marketed Targeted Therapeutics
Table 11.9. TIL Therapy: Historical Development of Treatment Protocols for Melanoma at the National Cancer Institute
Table 11.10. T-Cell Immunotherapies: TIL Therapies under Investigation for Metastatic Melanoma
Table 11.11. Lung Cancer: List of Marketed Targeted Therapeutics
Table 11.12. T-Cell Immunotherapies: Targets under Investigation for Lung Cancer
Table 11.13. Pancreatic Cancer: List of Marketed Targeted Therapeutics
Table 11.14. T-Cell Immunotherapies: Targets under Investigation for Pancreatic Cancer
Table 11.15. Liver Cancer: List of Marketed Targeted Therapeutics
Table 11.16. CAR-T Cell Therapies: Targets under Investigation for Liver Cancer
Table 11.17. TCR-based Therapies: Targets under Investigation for Liver Cancer
Table 11.18. Breast Cancer: List of Marketed Targeted Therapeutics
Table 11.19. CAR-T Cell Therapies: Targets under Investigation for Breast Cancer
Table 11.20. TCR-based Therapies: Targets under Investigation for Breast Cancer
Table 11.21. Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 11.22. T-Cell Immunotherapies: Targets under Investigation for Ovarian Cancer
Table 11.23. Bladder Cancer: List of Marketed Targeted Therapeutics
Table 11.24. Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
Table 12.1. Editas Medicine: CRISPR / Cas9 Technology, Research Publications
Table 12.2. Editas Medicine: Funding Instances
Table 12.3. Editas Medicine: Collaborations
Table 12.4. Intellia Therapeutics: CRISPR / Cas9 Technology, Research Publications
Table 12.5. Intellia Therapeutics: Funding Instances
Table 11.6. Intellia Therapeutics: Collaborations
Table 11.7. CRISPR Therapeutics: CRIPSR / Cas9 Technology, Research Publications
Table 12.8. CRISPR Therapeutics: Funding Instances
Table 12.9. CRISPR Therapeutics: Collaborations
Table 12.10. Beam Therapeutics: Funding Instances
Table 12.11. Beam Therapeutics: Collaborations
Table 12.12. Gracell Biotechnologies: Funding Instances
Table 12.13. Cellectis: Funding Instances
Table 12.14.  Cellectis: Collaborations
Table 12.15. bluebird bio: megaTAL Technology, Research Publications
Table 12.16. bluebird bio: Funding Instances
Table 12.17. bluebird bio: Collaborations
Table 12.18. Sangamo Therapeutics: Funding Instances
Table 12.19. Sangamo Therapeutics: Collaborations
Table 12.20. Unum Therapeutics: Funding Instances
Table 12.21. Unum Therapeutics: Collaborations
Table 12.22. Celyad: Funding Instances
Table 12.23. Celyad: Collaborations
Table 12.24. Glycostem: Funding Instances
Table 12.25. Glycostem: Collaborations
Table 12.26. Intrexon: Funding Instances
Table 12.27. Intrexon: Collaborations
Table 12.28. Bellicum Pharmaceuticals: Key Switch Technologies
Table 12.29. Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 12.30. Bellicum Pharmaceuticals: Funding Instances
Table 12.31. Bellicum Pharmaceuticals: Collaborations
Table 12.32. Theravectys: Funding Instances
Table 12.33. Technologies for CAR-T Safety Enhancement
Table 12.34. Formula Pharmaceuticals: Collaborations
Table 13.1. T-Cell Immunotherapies Market: Partnerships and Collaborations, 2005-2019 (till April)
Table 14.1. T-Cell Immunotherapies: Funding and Investments, Pre-2009 to 2019
Table 14.2. T-Cell Immunotherapies: Summary of Investments
Table 15.1. List of Other Novel T-Cell Immunotherapies
Table 15.2. Treg Cells: Properties
Table 16.1. Assessment Strategies for Different Manufacturing Processes
Table 16.2. Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 16.3. Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 16.4. Cell Therapy Manufacturing: Contract Manufacturers
Table 17.1. Price of Marketed Gene / Cell Therapies
Table 17.2. Price of Marketed Targeted Drugs
Table 17.3. T-Cell Immunotherapies: Expert Opinions on Pricing
Table 17.4. CAR-T Cell Therapies: Reimbursement Landscape
Table 18.1. T-Cell Immunotherapies: List of Forecasted Molecules
Table 18.2. Kymriah (Novartis): Net Present Value (USD Million)
Table 18.3. Kymriah (Novartis): Value Creation Analysis (USD Million)
Table 18.4. Yescarta (Gilead Sciences): Net Present Value (USD Million)
Table 18.5. Yescarta (Gilead Sciences): Value Creation Analysis (USD Million)
Table 18.6. bb2121 (bluebird bio / Celgene): Net Present Value (USD Million)
Table 18.7. bb2121 (bluebird bio / Celgene): Value Creation Analysis (USD Million)
Table 18.8. LCAR-B38M (Nanjing Legend Biotech /Janssen): Net Present Value (USD Million)
Table 18.9. LCAR-B38M (Nanjing Legend Biotech /Janssen): Value Creation Analysis (USD Million)
Table 18.10. MB-CART19.1 (Miltenyi Biotec): Net Present Value (USD Million)
Table 18.11. MB-CART19.1 (Miltenyi Biotec): Value Creation Analysis (USD Million)
Table 18.12. CD19 CAR-T (Sinobioway Cell Therapy): Net Present Value (USD Million)
Table 18.13. CD19 CAR-T (Sinobioway Cell Therapy): Value Creation Analysis (USD Million)
Table 18.14. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Net Present Value (USD Million)
Table 18.15. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Value Creation Analysis (USD Million)
Table 18.16. AUTO2 (Autolus): Net Present Value (USD Million)
Table 18.17. AUTO2 (Autolus): Value Creation Analysis (USD Million)
Table 18.18. AUTO3 (Autolus): Net Present Value (USD Million)
Table 18.19. AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 18.20. GPC3 CAR-T (Shanghai GeneChem): Net Present Value (USD Million)
Table 18.21. GPC3 CAR-T (Shanghai GeneChem): Value Creation Analysis (USD Million)
Table 18.22. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
Table 18.23. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
Table 18.24. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
Table 18.25. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
Table 18.26. CD19 CAR-T (Shanghai Bioray Laboratory): Net Present Value (USD Million)
Table 18.27. CD19 CAR-T (Shanghai Bioray Laboratory): Value Creation Analysis (USD Million)
Table 18.28. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 18.29. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 18.30. PCAR-019 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 18.31. PCAR-019 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 18.32. TBI-1501 (Takara Bio): Net Present Value (USD Million)
Table 18.33. TBI-1501 (Takara Bio): Value Creation Analysis (USD Million)
Table 18.34. IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 18.35. IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Value Creation Analysis (USD Million)
Table 18.36. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD Million)
Table 18.37. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
Table 18.38. BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 18.39. BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 18.40. CARCIK-CD19 (Formula Pharmaceuticals): Net Present Value (USD Million)
Table 18.41. CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
Table 18.42. EGFR CART (The Beijing Pregene Science and Technology): Net Present Value (USD Million)
Table 18.43. EGFR CART (The Beijing Pregene Science and Technology): Value Creation Analysis (USD Million)
Table 18.44. ANTI-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Net Present Value (USD Million)
Table 18.45. ANTI-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Value Creation Analysis (USD Million)
Table 18.46. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Net Present Value (USD Million)
Table 18.47. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Value Creation Analysis (USD Million)
Table 18.48. IMCgp100 (Immunocore): Net Present Value (USD Million)
Table 18.49. IMCgp100 (Immunocore): Value Creation Analysis (USD Million)
Table 18.50. TBI-1301 (Takara Bio): Net Present Value (USD Million)
Table 18.51. TBI-1301 (Takara Bio): Value Creation Analysis (USD Million)
Table 18.52. ALT 801 (Altor BioScience): Net Present Value (USD Million)
Table 18.53. ALT 801 (Altor BioScience): Value Creation Analysis (USD Million)
Table 18.54. JTCR016 (Juno Therapeutics): Net Present Value (USD Million)
Table 18.55. JTCR016 (Juno Therapeutics): Value Creation Analysis (USD Million)
Table 18.56. LioCyx (Lion TCR): Net Present Value (USD Million)
Table 18.57. LioCyx (Lion TCR): Value Creation Analysis (USD Million)
Table 18.58. YT-E001 (China Immunotech): Net Present Value (USD Million)
Table 18.59. YT-E001 (China Immunotech): Value Creation Analysis (USD Million)
Table 18.60. TILs (Nantes University Hospital): Net Present Value (USD Million)
Table 18.61. TILs (Nantes University Hospital): Value Creation Analysis (USD Million)
Table 18.62. TILs (Netherland Cancer Institute): Net Present Value (USD Million)
Table 18.63. TILs (Netherland Cancer Institute): Value Creation Analysis (USD Million)
Table 18.64. Lifileucel (LN-144) (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 18.65. TILs (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 18.66. LN-145 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 18.67. LN-145 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 18.68. LTX-315 and TILs (Lytix Biopharma): Net Present Value (USD Million)
Table 18.69. LTX-315 and TILs (Lytix Biopharma): Value Creation Analysis (USD Million)
Table 19.1. KYMRIAH®: Drug Overview
Table 19.2. YESCARTA®: Drug Overview
Table 20.1. Adaptimmune Therapeutics: Company Profile
Table 20.2. Autolus: Company Profile
Table 20.3. bluebird bio: Company Profile
Table 20.4. CARsgen Therapeutics: Company Profile
Table 20.5. Celgene: Company Profile
Table 20.6. Cell Medica: Company Profile
Table 20.7. Cellectis: Company Profile
Table 20.8. Cellular Biomedicine Group: Company Profile
Table 20.9. Immunocore: Company Profile
Table 20.10. Innovative Cellular Therapeutics: Company Profile
Table 20.11. Iovance Biotherapeutics: Company Profile
Table 20.12. Kite Pharma: Company Profile
Table 20.13. Lion TCR: Company Profile
Table 20.14. Noile-Immune Biotech: Company Profile
Table 20.15. Novartis: Company Profile
Table 20.16. Shanghai Genechem: Company Profile
Table 20.17. Sinobioway Cell Therapy: Company Profile
Table 20.18. Takara Bio: Company Profile
Table 20.19. Unum Therapeutics: Company Profile
Table 20.20. ZIOPHARM Oncology: Company Profile
Table 23.1. T-Cell Immunotherapies: Analysis by Type of Product
Table 23.2. T-Cell Immunotherapies: Analysis by Type of Developer
Table 23.3. T-Cell Immunotherapies: Analysis by Type of Developer and Type of Product
Table 23.4. T-Cell Immunotherapies: Analysis by Phase of Development
Table 23.5. T-Cell Immunotherapies: Analysis by Phase of Development and Type of Product
Table 23.6. T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Table 23.7. T-Cell Immunotherapies: Analysis by Target Therapeutic Area and Type of Product
Table 23.8. T-Cell Immunotherapies: Analysis by Popular Target Indications
Table 23.9. CAR-T Cell Immunotherapies: Analysis by Popular Target Indications
Table 23.10. TCR-based Immunotherapies: Analysis by Popular Target Indications
Table 23.11. TIL-based Immunotherapies: Analysis by Popular Target Indications
Table 23.12. CAR-T Cell Immunotherapies: Analysis by Target Antigen
Table 23.13. TCR-based Immunotherapies: Analysis by Target Antigen
Table 23.14. T-Cell Immunotherapies: Analysis by Source of T-Cells
Table 23.15. T-Cell Immunotherapies: Analysis by Source of T-Cells and Type of Product
Table 23.16. T-Cell Immunotherapies: Analysis by Route of Administration
Table 23.17. T-Cell Immunotherapies: Analysis by Route of Administration and Type of Product
Table 23.18. T-Cell Immunotherapies: Analysis by Patient Segment
Table 23.19. T-Cell Immunotherapies: Analysis by Patient Segment and Type of Product
Table 23.20. T-Cell Immunotherapies: Analysis by Type of Therapy
Table 23.21. T-Cell Immunotherapies: Analysis by Type of Therapy and Type of Product
Table 23.22. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Clinical Development
Table 23.23. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 23.24. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Table 23.25. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Table 23.26. T-Cell Immunotherapies: Popular Targets in Hematological Cancer
Table 23.27. T-Cell Immunotherapies: Popular Targets in Solid Tumor
Table 23.28. CAR-Construction: Analysis by Generation of CAR-T Therapies
Table 23.29. CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
Table 23.30. CAR-Construction: Analysis by Type of Vector
Table 23.31. CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Table 23.32. CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Table 23.33. CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
Table 23.34. Partnerships and Collaborations: Cumulative Trend by Year, 2005-2019
Table 23.35. Partnerships and Collaborations: Year-Wise Trend of Industry vs Non-Industry Partnerships, 2005-2019
Table 23.36. Partnerships and Collaborations: Distribution by Type of Partnership
Table 23.37. Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2016 and 2016-2019
Table 23.38. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 23.39. Partnerships and Collaborations: Distribution by Type of Product and Year-Wise Trend
Table 23.40. Partnerships and Collaborations: Distribution by Type of Industry
Table 23.41. Partnerships and Collaborations: Distribution by Type of Industry and Type of Product
Table 23.42. Partnerships and Collaborations: Distribution by Individual Products
Table 23.43. Partnerships and Collaborations: Most Active Industry Players
Table 23.44. Partnerships and Collaborations: Most Active Non-Industry Players
Table 23.45. Partnerships and Collaborations: Most Active Contract Manufacturers
Table 23.46. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution of Manufacturing Agreements
Table 23.47. Partnerships and Collaborations: Regional Distribution
Table 23.48. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 23.49. Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre 2012-2019
Table 23.50. Funding and Investment Analysis: Cumulative Amount Invested, Pre 2012-2019 (USD Million)
Table 23.51. Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre 2012-2019
Table 23.52. Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, Pre 2012-2019 (USD Million)
Table 23.53. Funding and Investments: Analysis by Amount Invested across Different Types of Products
Table 23.54. Most Active Players: Distribution by Number of Instances
Table 23.55. Funding and Investments: Analysis by Amount Invested across Different Types of Investors
Table 23.56. Most Active Investors: Distribution by Number of Instances
Table 23.57. Funding and Investment Analysis: Distribution by Geography
Table 23.58. Funding and Investment Analysis: Analysis by Amount Invested across Different Countries (USD Million)
Table 23.59. Other T-Cell Immunotherapies: Analysis by Phase of Development
Table 23.60. Other T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Table 23.61. Other T-Cell Immunotherapies: Analysis by Type of Cells
Table 23.62. Other T-Cell Immunotherapies: Analysis by Source of T-Cells
Table 23.63. Overall T-Cell Immunotherapies Market, 2019-2030: Conservative Scenario (USD Billion)
Table 23.64. Overall T-Cell Immunotherapies Market, 2019-2030: Base Scenario (USD Billion)
Table 23.65. Overall T-Cell Immunotherapies Market, 2019-2030: Optimistic Scenario (USD Billion)
Table 23.66. T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2030 (USD Billion)
Table 23.67. T-Cell Immunotherapy Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Table 23.68. T-Cell Immunotherapy Market: Distribution by Target Antigens(s), 2025 and 2030 (USD Billion)
Table 23.69. T-Cell Immunotherapy Market:  Key Players, 2025 and 2030 (USD Billion)
Table 23.70. T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 23.71. Overall CAR-T Cell Therapies Market, 2019-2030: Conservative Scenario (USD Billion)
Table 23.72. Overall CAR-T Cell Therapies Market, 2019-2030: Base Scenario (USD Billion)
Table 23.73. Overall CAR-T Cell Therapies Market, 2019-2030: Optimistic Scenario (USD Billion)
Table 23.74. CAR-T Cell Therapies Market: Distribution by Target Indication(s) (USD Billion)
Table 23.75. CAR-T Cell Therapies Market: Distribution by Target Antigen(s) (USD Billion)
Table 23.76. CAR-T Cell Therapies Market:  Key Players (USD Billion)
Table 23.77. CAR-T Cell Therapies Market: Distribution by Geography (USD Billion)
Table 23.78. KYMRIAH® (Novartis) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.79. KYMRIAH® (Novartis) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.80. KYMRIAH® (Novartis) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.81. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.82. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.83. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.84. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.85. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.86. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.87. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.88. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.89. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.90. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.91. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.92. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.93. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.94. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.95. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.96. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.97. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.98. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.99. AUTO2 (Autolus) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.100. AUTO2 (Autolus) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.101. AUTO2 (Autolus) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.102. AUTO3 (Autolus) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.103. AUTO3 (Autolus) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.104. AUTO3 (Autolus) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.105. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.106. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.107. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.108. BCMA CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.109. BCMA CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.110. BCMA CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.111. CD19 CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.112. CD19 CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.113. CD19 CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.114. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.115. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.116. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.117. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.118. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.119. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.120. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.121. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.122. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.123. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.124. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.125. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.126. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.127. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.128. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.129. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.130. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.131. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.132. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.133. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.134. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.135. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.136. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.137. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.138. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.139. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.140. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.141. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.142. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.143. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.144. Overall TCR-based Therapies Market Forecast, 2019-2030: Conservative Scenario (USD Billion)
Table 23.145. Overall TCR-based Therapies Market Forecast, 2019-2030: Base Scenario (USD Billion)
Table 23.146. Overall TCR-based Therapies Market Forecast, 2019-2030: Optimistic Scenario (USD Billion)
Table 23.147. TCR-Based Therapies Market: Distribution by Target Indication(s) (USD Billion)
Table 23.148. TCR-Based Therapies Market: Distribution by Target Antigen(s) (USD Billion)
Table 23.149. TCR-Based Therapies Market:  Key Players (USD Billion)
Table 23.150. TCR-Based Therapies Market: Distribution by Geography (USD Billion)
Table 23.151. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.152. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.153. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.154. IMCgp100 (Immunocore) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.155. IMCgp100 (Immunocore) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.156. IMCgp100 (Immunocore) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.157. TBI-1301 (Takara Bio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.158. TBI-1301 (Takara Bio) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.159. TBI-1301 (Takara Bio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.160. ALT-801 (Altor Bioscience) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.161. ALT-801 (Altor Bioscience) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.162. ALT-801 (Altor Bioscience) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.163. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.164. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.165. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.166. LioCyx (Lion TCR) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.167. LioCyx (Lion TCR) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.168. LioCyx (Lion TCR) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.169. YT-E001 (China Immunotech) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.170. YT-E001 (China Immunotech) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.171. YT-E001 (China Immunotech) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.172. Overall TIL-based Therapies Market Forecast, 2019-2030: Conservative Scenario (USD Billion)
Table 23.173. Overall TIL-based Therapies Market Forecast, 2019-2030: Base Scenario (USD Billion)
Table 23.174. Overall TIL-based Therapies Market Forecast, 2019-2030: Optimistic Scenario (USD Billion)
Table 23.175. TIL-Based Therapies Market: Distribution by Target Indication(s) (USD Billion)
Table 23.176. TIL-Based Therapies Market:  Key Players (USD Billion)
Table 23.177. TIL-Based Therapies Market: Distribution by Target Geography (USD Billion)
Table 23.178. TILs (Nantes University Hospital) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.179. TILs (Nantes University Hospital) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.180. TILs (Nantes University Hospital) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.181. TILs (The Netherlands Cancer Institute) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.182. TILs (The Netherlands Cancer Institute) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.183. TILs (The Netherlands Cancer Institute) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.184. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.185. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.186. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.187. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.188. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.189. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.190. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.191. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.192. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030s: Optimistic Scenario (USD Million)
Table 23.193. T-Cell Immunotherapy Market Forecast, 2019, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3P Biopharmaceuticals
  2. A*STAR’s Genome Institute of Singapore
  3. AbbVie Ventures
  4. Abramson Cancer Center
  5. AbCheck
  6. AbClon
  7. Abingworth
  8. AbVitro
  9. ACEA Biosciences
  10. Acerta Pharma
  11. Acer Therapeutics
  12. Acorn Pacific Ventures
  13. Adage Capital Management
  14. Adaptimmune Therapeutics
  15. Adicet Bio
  16. Adimab
  17. Advanced BioScience Laboratories
  18. Advent Bioservices
  19. Adverum Biotechnologies
  20. Aeon Therapeutics
  21. AFG Private Equity
  22. Affiliated Hospital to Academy of Military Medical Sciences
  23. Agent Capital
  24. AgenTus Therapeutics
  25. Agreen Biotech
  26. AGF Private Equity
  27. Aisling Capital
  28. Alberta Cell Therapy Manufacturing
  29. Allele Biotechnology and Pharmaceuticals
  30. Aokai Biotech
  31. Akron Biotech
  32. AK (Suzhou) Biomedical
  33. Alaska Permanent Fund
  34. Albert Einstein College of Medicine
  35. Alexandria Venture Investments
  36. Allergan
  37. Allife Medical Science and Technology
  38. Allogene Therapeutics
  39. Alta Partners
  40. Alpine Immune Sciences
  41. Altor BioScience
  42. Amsterdam BioTherapeutics Unit
  43. Amgen
  44. Andalusian Initiative for Advanced Therapies
  45. Anhui Kedgene Biotechnology
  46. Anhui Provincial Hospital
  47. Antagene
  48. Anterogen
  49. apceth Biopharma
  50. Aquilo Capital Management
  51. ARBELE
  52. ARCH Venture Partners
  53. Argos Therapeutics
  54. ARIAD Pharmaceuticals
  55. Arix Bioscience
  56. ArrowMark Partners
  57. Asahi Glass Company
  58. Asterias Biotherapeutics
  59. Astellas Pharma
  60. AstraZeneca
  61. Asymptote
  62. Atara Biotherapeutics
  63. AT Impf
  64. Atlantic Bio GMP
  65. Atlas Venture
  66. Atossa Genetics
  67. Atreca
  68. Aurora Biopharma
  69. Autolus
  70. Avacta
  71. AVICT Global Holdings
  72. Baader Bank
  73. Bank Degroof Petercam
  74. BankInvest Biomedical Venture
  75. Barclays
  76. Bausch Health
  77. Batavia Biosciences
  78. Bavarian Nordic
  79. Baxalta
  80. Bayer
  81. Baylor College of Medicine
  82. Be The Match BioTherapies
  83. Beijing Biohealthcare Biotechnology
  84. Beijing Doing Biomedical
  85. Beijing Genomics Institute
  86. Beijing Immunochina Medical Science and Technology
  87. Beijing Mario Biotechnology
  88. Beijing Sanwater Biological Technology
  89. Beijing You’an Hospital
  90. Bellicum Pharmaceuticals
  91. Bellco Capital
  92. Beth Israel Deaconess Medical Center
  93. Bezos Expeditions
  94. Bill & Melinda Gates Foundation
  95. BioAtla
  96. Bioceltech Therapeutics
  97. Bio Elpida
  98. Biogen
  99. BioLife Solutions
  100. Bioinova
  101. Biomedical Catalyst
  102. BioNTech
  103. bluebird bio
  104. BMO Capital Markets
  105. Boehringer Ingelheim
  106. BofA Securities
  107. Bone Therapeutics
  108. Boston Children's Hospital
  109. Boxer Capital
  110. Brace Pharma Capital
  111. Brammer Bio
  112. Bristol-Myers Squibb
  113. Cabaret Biotech
  114. Caladrius Biosciences
  115. California Institute for Regenerative Medicine
  116. Canaan Partners
  117. Cancer Research UK
  118. Cancer Prevention Research Institute of Texas
  119. Cantor Fitzgerald
  120. Captain T Cell
  121. Capricor Therapeutics
  122. Cardiff University
  123. Cartherics
  124. Caribou Biosciences
  125. Carina Biotech
  126. CARsgen Therapeutics
  127. Cartesian Therapeutics
  128. Cartherics
  129. Casdin Capital
  130. Casebia Therapeutics
  131. Cell Biotech
  132. Celdara Medical
  133. Cellectis
  134. Cell Design Labs
  135. Celgene
  136. Cell and Gene Therapy Catapult
  137. Cellenkos
  138. Cellin Technologies
  139. Cell Medica
  140. Cellular Biomedicine Group
  141. CELLforCURE
  142. Cell Tech Pharmed
  143. Cell Therapies
  144. Cooperative Research Centre for Cell Therapy Manufacturing
  145. Cellular Therapeutics
  146. Celyad
  147. Center for Cell and Gene Therapy
  148. Center for Cell Manufacturing Ireland, National University of Ireland Galway
  149. Changhai Hospital
  150. CHDI Foundation
  151. Chengdu MedGenCell
  152. Chengdu Miaoji Medical Technology
  153. Chiesi Farmaceutici
  154. China Immunotech
  155. China Regenerative Medicine International
  156. Children's Hospital of Philadelphia
  157. Children's Mercy Hospital
  158. Children's Oncology Group
  159. Children's Research Institute
  160. Chinese Academy of Sciences
  161. Chinese PLA General Hospital
  162. Christie NHS Foundation Trust
  163. Clough Capital Partners
  164. Citigroup
  165. City of Hope National Medical Center
  166. Cognate BioServices
  167. Columbia University
  168. Cook MyoSite
  169. Copenhagen University Hospital
  170. Cormorant Asset Management
  171. Cowen Private Investments
  172. CRISPR Therapeutics
  173. Cryoport
  174. Cryosite
  175. CTI Clinical Trial and Consulting Services
  176. Curative Ventures
  177. CureVac
  178. Cystic Fibrosis Foundation Therapeutics
  179. CytoLumina Technologies
  180. Cytovance Biologics
  181. Daiichi Sankyo
  182. Dana-Farber Cancer Institute
  183. Dangdai International Group
  184. Dartmouth College
  185. Deerfield Management
  186. Delenex Therapeutics
  187. Dendreon
  188. Deutsche Bank Securities
  189. dievini Hopp Biotech
  190. Direct Selling Association of Malaysia
  191. Ditch Plains Capital Management
  192. Dongguan People's Hospital
  193. Dow AgroSciences
  194. DFJ Venture Capital
  195. DS Asset Management
  196. Duke Cancer Institute
  197. EcoR1 Capital
  198. Editas Medicine
  199. Edmond de Rothschild Investment Partners
  200. Efung Capital
  201. Eli Lilly
  202. Emory Personalized Immunotherapy Core
  203. Endocyte
  204. ERS Genomics
  205. European Commission
  206. Eurostars
  207. Eutilex
  208. Eureka Therapeutics
  209. EXUMA Biotechnology
  210. F1 BioVentures
  211. F1 Oncology
  212. F2 Ventures
  213. Fate Therapeutics
  214. Fetolumina Technologies
  215. Financière IDAT
  216. Finnish Funding Agency for Technology and Innovation
  217. First Affiliated Hospital of Chengdu Medical College
  218. First Affiliated Hospital of Harbin Medical University
  219. First Affiliated Hospital of Sun Yat-sen University
  220. First Affiliated Hospital of Wenzhou Medical University
  221. First Affiliated Hospital of Zhejiang University
  222. First People's Hospital of Foshan
  223. F-Prime Capital
  224. Five Prime Therapeutics
  225. Five Rings Financial
  226. Fondazione Telethon and Ospedale San Raffaele
  227. Foresite Capital
  228. Forevertek Biotechnology
  229. Formula Pharmaceuticals
  230. Fortress Biotech
  231. Fosun Pharmaceutical
  232. Franklin Templeton Investments
  233. Fred Hutchinson Cancer Research Center
  234. Fraunhofer Institute for Cell Therapy and Immunology
  235. Friedreich’s Ataxia Research Alliance
  236. Froceth
  237. Fuda Cancer Hospital
  238. Fudan University
  239. FUJIFILM Cellular Dynamics
  240. Fujian Medical University
  241. Gamida Cell
  242. GammaCell Bio-Technologies
  243. GammaDelta Therapeutics
  244. Gadeta
  245. Gene and Cell Therapy Lab
  246. GE Healthcare Life Sciences
  247. Genentech
  248. GenCure
  249. Genmab
  250. Genus Oncology
  251. German Federal Ministry of Education and Research
  252. Ghent University Hospital
  253. GigaGen
  254. Gilead Sciences
  255. GlaxoSmithKline
  256. Glycostem
  257. G.N. Tech Venture Capital
  258. Goldman Sachs
  259. GP Capital
  260. Gracell Biotechnologies
  261. Green Cross Cell
  262. Guggenheim Securities
  263. Guangdong Xiangxue Precision Medical Technology
  264. Guangzhou Anjie Biomedical Technology
  265. Guangzhou FineImmune Biotechnology
  266. Guangzhou Yiyang Biological Technology
  267. Guangzhou Eighth People's Hospital
  268. Guangzhou First People's Hospital
  269. Guangzhou Xiangxue Pharmaceutical
  270. Guangdong Zhaotai InVivo Biomedicine
  271. Guy's and St Thomas' NHS Foundation Trust
  272. Hadassah Medical Center
  273. Haitong International Securities
  274. Hangzhou Cancer Hospital
  275. Harbin Medical University
  276. Harvard University
  277. H.C. Wainwright
  278. Hebei Senlang Biotechnology
  279. Hebei Yanda Ludaopei Hospital
  280. Helix BioPharma
  281. Helixmith
  282. Henan Cancer Hospital
  283. Henan Hualong Biotechnology
  284. HengRui YuanZheng Bio-Technology
  285. Herlev Hospital
  286. Hillhouse Capital Group
  287. Histocell
  288. Hitachi Chemical Advanced Therapeutics Solutions
  289. H. Lee Moffitt Cancer Center and Research Institute
  290. Horizon Discovery
  291. Horizon Technology Finance
  292. Howard Hughes Medical Institute
  293. Hrain Biotechnology
  294. Human Stem Cells Institute
  295. Hunan Yongren Medical Innovation
  296. iCarTAB BioMed
  297. iCell Gene Therapeutics
  298. Icell Kealex Therapeutics
  299. ICON
  300. Immatics Biotechnologies
  301. Immunocore
  302. Immune Therapeutics
  303. Immunovative Therapies
  304. Imperial College London
  305. Imperial Innovations Group
  306. Innovate UK
  307. Innovative Cellular Therapeutics
  308. Innovative Genomins Institute
  309. Intellia Therapeutics
  310. Intrexon
  311. Institut Curie
  312. Institut Pasteur
  313. Invectys
  314. Invesco Perpetual
  315. Investing Women
  316. Instituto de Salud Carlos III
  317. Iovance Biotherapeutics
  318. Iowa State University Research Foundation
  319. Janus Capital Management
  320. Janssen Biotech
  321. Japan Science and Technology Agency
  322. Jazz Pharmaceuticals
  323. JCR Pharmaceuticals
  324. Jefferies Group
  325. Jennison Associates
  326. Jiangsu Cancer Hospital
  327. JIG Genesis Fountain Healthcare Ventures
  328. John Goldman Centre for Cellular Therapy
  329. Johns Hopkins University
  330. Jolly Innovation Ventures
  331. Jonsson Comprehensive Cancer Center
  332. JMP Group
  333. J.P. Morgan Securities
  334. Juno Therapeutics
  335. JW Biotechnology
  336. KAEDI
  337. Kaitai Capital
  338. Karolinska University Hospital
  339. Karst Peak Capital
  340. KBI Biopharma
  341. Keio University
  342. Key Biologics
  343. King's College London
  344. Kington Capital
  345. Kite Pharma
  346. Kolon Investment
  347. KTB Ventures
  348. Laurion Capital Management
  349. Leerink Partners
  350. Legend Capital
  351. Leiden University Medical Center
  352. Leucid Bio
  353. Level One Partners
  354. Lexicon Pharmaceuticals
  355. LifeForce Capital
  356. Life Technologies
  357. Lifeline Ventures
  358. LifeSci Capital
  359. Lightstone Ventures
  360. Lilly Asia Ventures
  361. Lion TCR
  362. Liminatus Pharma
  363. Lincoln Park Capital Fund
  364. Living Pharmaceticals
  365. Lonza
  366. Loughborough University
  367. Loyola University
  368. Longitude Capital
  369. Lucion Group
  370. Lupus Ventures
  371. LVC Super Unicorn Fund
  372. Lübeck Institute of Experimental Dermatology
  373. Lytix Biopharma
  374. MabQuest
  375. MabVax Therapeutics Holdings
  376. Malin
  377. Marino Biotechnology
  378. MaSTherCell
  379. Massachusetts General Hospital Cancer Center
  380. MaxCyte
  381. Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  382. Maxim Group
  383. Mayo Clinic Ventures
  384. MD Anderson Cancer Center
  385. Medarex
  386. Medical College of Wisconsin
  387. Medicxi Ventures
  388. Medigene
  389. MEDINET
  390. MedImmune
  391. Medisix Therapeutics
  392. Medpost Urgent Care
  393. Memorial Sloan Kettering Cancer Center
  394. Merck
  395. Merck Serono
  396. Merlin Nexus
  397. Mesoblast
  398. Mie University
  399. Millennium Pharmaceuticals (acquired by Takeda Oncology)
  400. Miller Value Partners
  401. Miltenyi Biotec
  402. MingJu Therapeutics Shanghai
  403. Minerva Biotechnologies
  404. Mirae Asset Financial Group
  405. Mission Bay Capital
  406. Moffitt Cancer Center
  407. Molecular and Cellular Therapeutics
  408. MolMed
  409. Morgan Stanley
  410. MPM Capital
  411. MSD Partners
  412. Mustang Bio
  413. Nanfang Hospital of Southern Medical University
  414. Nanjing Children's Hospital
  415. Nanjing Legend Biotech
  416. Nantes University Hospital
  417. NantKwest
  418. National Cancer Institute
  419. National Heart, Lung, and Blood Institute
  420. National Institute of Allergy and Infectious Diseases
  421. National Institutes of Health
  422. National University of Singapore
  423. Navy General Hospital (Beijing)
  424. NCL Innovation
  425. Netherlands Cancer Institute
  426. New Enterprise Associates
  427. New Leaf Venture Partners
  428. New York Medical College
  429. Nextech Invest
  430. Ningbo Cancer Hospital
  431. Nikon CeLL innovation
  432. Nipro
  433. Nohla Therapeutics
  434. Noile-Immune Biotech
  435. Northland Capital Markets
  436. Novadip Biosciences
  437. Novartis
  438. Novo Ventures
  439. Oaktree Capital Management
  440. Obsidian Therapeutics
  441. OCV Partners
  442. ODYSSEE Venture
  443. Omega Funds
  444. Oncodesign
  445. OncoTracker
  446. OnCyte
  447. Ono Pharmaceutical
  448. Onyx Pharmaceuticals
  449. Opexa Therapeutics
  450. Opus Bio
  451. OrbiMed HealthCare Fund Management
  452. Oriza Seed Capital
  453. Osage University Partners
  454. Bambino Gesù Hospital
  455. Oxford BioMedica
  456. Oxford MEStar
  457. PACT Pharma
  458. Panacea Ventures
  459. Parker Institute for Cancer Immunotherapy
  460. PCI Services
  461. PCT Cell Therapy Services
  462. Peking University
  463. Pentwater Capital Management
  464. PeproMene Bio
  465. Perceptive Advisors
  466. Peter Thiel
  467. Petercam
  468. Peter MacCallum Cancer Centre
  469. Perceptive Advisors
  470. PersonGen BioTherapeutics (Suzhou)
  471. Pfizer
  472. PharmaBio
  473. PharmaCell
  474. Pharmicell
  475. Phio Pharmaceuticals
  476. Photon Fund
  477. Ping An Ventures
  478. Piper Jaffray
  479. Pinze Lifetechnology
  480. Pluristem Therapeutics
  481. PolyBioCept
  482. Pontifax
  483. Poseida Therapeutics
  484. Praxis Pharmaceutical
  485. Precision BioSciences
  486. Precision Genome Engineering
  487. Princess Margaret Cancer Centre
  488. ProMab Biotechnologies
  489. Promethera Biosciences
  490. Prometheus Laboratories
  491. Provia Laboratories
  492. Puma Biotechnology
  493. PureTech Health
  494. Qingzhe Capital
  495. Quogue Capital
  496. QVT Financial
  497. RA Capital Management
  498. Raymond James
  499. Rayne Cell Therapy Suite
  500. RedoxTherapies (acquired by Juno Therapeutics)
  501. Redmile Group
  502. Relieve Genetics
  503. Regeneron Pharmaceuticals
  504. Remeditex Ventures
  505. Renji Hospital
  506. Renmin Hospital of Wuhan University
  507. Ridgeback Capital Management
  508. Riyadh Pharma
  509. Roche
  510. Rockland Immunochemicals
  511. Rockspring Capital
  512. Roger Williams Medical Center
  513. RoslinCT
  514. Roswell Park Comprehensive Cancer Center
  515. Royal Adelaide Hospital
  516. RXi Pharmaceuticals
  517. Sabby Management
  518. Samsara BioCapital
  519. Sangamo Therapeutics
  520. Sanofi-Genzyme BioVentures
  521. San Raffaele Hospital
  522. Scotia Biologics
  523. Scottish National Blood Transfusion Service
  524. Scottish Investment Bank
  525. Seattle Genetics
  526. Seattle Children's Hospital
  527. Second Affiliated Hospital of Guangzhou Medical University
  528. Sectoral Asset Management
  529. Second Military Medical University
  530. Sequoia Capital China
  531. Servier
  532. Shanghai Bioray Laboratory
  533. Shanghai Changzheng Hospital
  534. Shanghai Cell Therapy Engineering Technology Research Center
  535. Shanghai Chest Hospital
  536. Shanghai Children's Medical Center
  537. Shanghai GeneChem
  538. Shanghai General Hospital
  539. Shanghai Houchao Biotechnology
  540. Shanghai iCELL Biotechnology
  541. Shanghai Jiao Tong University School of Medicine
  542. Shanghai Longyao Biotechnology
  543. Shanghai Sinobioway Sunterra Biotechnology
  544. Shanghai Sunway Biotech
  545. Shanghai Tongji Hospital
  546. Shanghai Unicar-Therapy Bio-medicine Technology
  547. Sheba Medical Center
  548. ShengJing360
  549. Shenzhen BinDeBio
  550. Shenzhen Geno-Immune Medical Institute
  551. Shenzhen Hornetcorn Biotechnology
  552. Shenzhen Institute for Innovation and Translational Medicine
  553. Shenzhen Second People's Hospital
  554. Sherpa Venture Capital
  555. Shire
  556. Shiyu Capital
  557. Shougang Fund
  558. Sibiono GeneTech
  559. Sidney Kimmel Comprehensive Cancer Center
  560. Sigma-Aldrich
  561. Shionogi
  562. Sichuan University
  563. Sinobioway Cell Therapy
  564. Sirona Capital
  565. SNU Bio Angel
  566. Southwest General Health Center
  567. Sorrento Therapeutics
  568. Spark Therapeutics
  569. Stage Cell Therapeutics
  570. Stanford University
  571. St. George's Hospital
  572. Stem Cell Institute
  573. Stifel
  574. St. Jude Children’s Research Hospital
  575. SOTIO
  576. StrideBio
  577. SR One
  578. SunTerra Capital
  579. SunTrust Robinson Humphrey
  580. Sun Yat-sen University
  581. Surveyor Capital
  582. SVB Leerink
  583. Syncona
  584. SyndicateRoom
  585. Synthace
  586. Symvivo
  587. Tactiva Therapeutics
  588. Taiho Ventures
  589. Takeda Pharmaceutical
  590. Takara Bio
  591. Targazyme
  592. Target ALS Foundation
  593. Tavistock Group
  594. TC BioPharm
  595. T-Cell Factory (acquired by Kite Pharma)
  596. TCR2 Therapeutics
  597. TCRCure Biopharma
  598. Tel Aviv Sourasky Medical Center
  599. Tekla Capital Management
  600. Temasek
  601. TeneoBio
  602. Tesaro (acquired by GSK)
  603. Tessa Therapeutics
  604. Tethys Health Ventures
  605. Terumo Medical
  606. T. Rowe Price Group
  607. Nanjing Drum Tower Hospital
  608. The Beijing Pregene Science and Technology
  609. The First Affiliated Hospital of Guangdong Pharmaceutical University
  610. The First Affiliated Hospital of Guangzhou Medical University
  611. The First Affiliated Hospital of Soochow University
  612. The First People's Hospital of Yunnan
  613. The First People's Hospital of Lianyungang
  614. The Longevity Fund
  615. The Pregene (ShenZhen) Biotechnology
  616. The Third Affiliated Hospital of Southern Medical University
  617. Thiel Capital
  618. The Ohio State University Comprehensive Cancer Center
  619. Theravectys
  620. The Research Council of Norway
  621. The Second Xiangya Hospital of Central South University
  622. The University of Sydney
  623. The University of Texas
  624. The University of Utah
  625. Henan University of Traditional Chinese Medicine
  626. Thermo Fisher Scientific
  627. The Wistar Institute
  628. Third Military Medical University
  629. Third Rock Ventures
  630. Third Security
  631. Three Arch Partners
  632. Tianjin Medical University Cancer Institute and Hospital
  633. Tianjin Mycure Medical Technology
  634. TiGenix
  635. TILT Biotherapeutics
  636. Timmune Biotech
  637. TissueGene-C
  638. Tmunity Therapeutics
  639. TNK Therapeutics
  640. Tongji University School of Medicine
  641. Touchstone Innovations
  642. TRACT Therapeutics
  643. TrakCel
  644. Transgene
  645. Transposagen Biopharmaceuticals
  646. Triumvira Immunologics
  647. TVAX Biomedical
  648. TVM Capital
  649. Two Blades Foundation
  650. TxCell (acquired by Sangmo)
  651. UBS
  652. UNC Lineberger Comprehensive Cancer Center
  653. Union Stem Cell & Gene Engineering
  654. Universal Cells
  655. University of Alberta
  656. University College London
  657. University Health Network
  658. University of Birmingham
  659. University of British Columbia
  660. University of California
  661. University of Florida
  662. University Hospital of Basel
  663. University of Lausanne
  664. University of Manchester
  665. University Medical Center Utrecht
  666. University of Milano-Bicocca
  667. University of Minnesota
  668. University of North Carolina
  669. University of Oxford
  670. University of Pennsylvania
  671. University of Rochester
  672. University of Zurich
  673. Uppsala University
  674. Unum Therapeutics
  675. Utrecht Holdings
  676. Vaccinogen
  677. Vecura
  678. venBio
  679. Venrock
  680. Vericel
  681. Versant Ventures
  682. Vertex Pharmaceuticals
  683. VGXI
  684. Vical
  685. Vi Ventures
  686. Vida Ventures
  687. ViGenCell
  688. Vivo Capital
  689. Viking Global Investors
  690. Vineti
  691. Vitruvian Networks
  692. Waisman Biomanufacturing
  693. Washington University
  694. Wedbush Securities
  695. Weill Cornell Medical College
  696. Wellcome Trust
  697. Wellington Management
  698. Wells Fargo Securities
  699. WH Partnership
  700. White Rock Capital Management
  701. William Blair
  702. WindMIL Therapeutics
  703. Woodford Investment Management
  704. Wu Capital
  705. Wuhan Union Hospital
  706. Wuhan Sian Medical Technology
  707. WuXi AppTec
  708. X-Body
  709. Xellbiogene
  710. Xiangxue Life Sciences
  711. Xiangxue Pharmaceutical
  712. Xinqiao Hospital
  713. Xijing Hospital
  714. Xuzhou Medical University
  715. Yake Biotechnology
  716. Yale University
  717. Yipu Capital
  718. YuanMing Capital
  719. Yuanyi Biotechnology
  720. Zelluna Immunotherapy
  721. Zhejiang Huahai Pharmaceutical
  722. Zhejiang University
  723. Zhujiang Hospital
  724. Ziopharm Oncology

Segmentation

The USD 26 billion (by 2030) financial opportunity within the T-cell immunotherapies market has been analyzed across the following segments:

  • Type of therapy
    • CAR-T cell therapy
    • TCR-based therapy
    • TIL-based therapy
  • Type of target disease indication
    • Acute lymphoblastic leukemia
    • Non-Hodgkin’s lymphoma
    • Melanoma
    • Bladder cancer
    • Lung cancer
    • Head and neck cancer
    • Multiple myeloma
    • Sarcoma
    • Chronic lymphocytic leukemia
    • Ovarian cancer
    • Esophageal cancer
    • Colorectal cancer
    • Nasopharyngeal carcinoma
    • Hepatocellular carcinoma
    • Acute myeloid leukemia
    • Renal cell carcinoma
  • Type of target antigens
    • CD19
    • BCMA
    • CD19/22
    • EGFR
    • NY-ESO-1
    • gp100
    • p53
    • EBV
    • MUC1
    • WT-1
    • Others
  • Key geographical regions 
    • North America
    • Europe
    • Asia Pacific

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com